### 1 TITLE

2 Systems immunology reveals the molecular mechanisms of heterogeneous influenza3 vaccine response in the elderly

4

### 5 AUTHORS

- 6 Saumya Kumar<sup>1,2#</sup>, Martijn Zoodsma<sup>1,2#</sup>, Nhan Nguyen<sup>1,2</sup>, Rodrigo Pedroso<sup>3</sup>, Stephanie
- 7 Trittel<sup>4</sup>, Peggy Riese<sup>4</sup>, Javier Botey-Bataller<sup>1,2,5</sup>, Liang Zhou<sup>1,2</sup>, Ahmed Alaswad<sup>1,2</sup>, Haroon
- 8 Arshad<sup>2,9</sup>, Mihai G. Netea<sup>5,6</sup>, Cheng-Jian Xu<sup>1,2,5</sup>, Frank Pessler<sup>1,7</sup>, Carlos A. Guzmán<sup>1,4</sup>, Luis
- 9 Graca<sup>3</sup>, Yang Li<sup>1,2,5,8,10,\*</sup>
- 10

# 11 AFFILIATIONS

- Centre for Individualised Infection Medicine (CiiM), a joint venture between the Helmholtz Centre for Infection Research (HZI) and Hannover Medical School (MHH), Feodor-Lynen-Straße 7, 30625 Hannover, Germany.
- TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research
   (HZI) and the Hannover Medical School (MHH), Feodor-Lynen-Straße 7, 30625
   Hannover, Germany.
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina,
   Universidade de Lisboa, Lisboa, Portugal.
- Department Vaccinology and Applied Microbiology, HZI, Inhoffenstraße 7, 38124
   Braunschweig, Germany
- Department of Internal Medicine and Radboud Center for Infectious Diseases,
   Radboud University Medical Center, Geert Grooteplein Zuid 8, 6525 GA Nijmegen,
   the Netherlands.
- 25 6. Department of Immunology and Metabolism, Life and Medical Sciences Institute
   26 (LIMES), University of Bonn, Bonn, Germany.
- Research Group Biomarkers for Infectious Diseases, TWINCORE, Feodor-Lynen Straße 7, 30625 Hannover, Germany.
- 8. Cluster of Excellence Resolving Infection Susceptibility (RESIST; EXC 2155),
   Hannover Medical School, Hannover, Germany.
- Present address: Department of Pharmaceutical Sciences, University of Faisalabad,
   Faisalabad 38000, Pakistan.
- 33

# 34 AUTHOR LIST FOOTNOTES

- 35 <sup>#</sup> These authors contributed equally
- 36 <sup>10</sup> Lead contact
- 37 \* Correspondence: <u>yang.li@helmholtz-hzi.de</u> (Y.L.)
- 38

# 39 HIGHLIGHTS

- 40 1. Pre-vaccination pro-inflammatory status impedes vaccine responsiveness in the 41 elderly.
- 42 2. Multi-omics integration reveals key molecules involved in vaccine response.
- 43 3. High pre-vaccination concentrations of IL-15 suppresses vaccine response through
   44 NK cell activation.
- 4. Certain long-chain fatty acids may act as modulators against chronic inflammationand are potential targets to improve vaccine response.
- 47 48

#### 49 SUMMARY

#### 

Vaccination-induced protection against influenza is greatly diminished and increasingly heterogeneous with age. We investigated longitudinally (up to five timepoints) a cohort of 234 elderly influenza vaccinees across two independent seasons including up to six modalities (multi-omics and immunological parameters). System-level analyses revealed responders exhibited time-dependent changes attributed to a productive vaccine response across all omics layers whereas non-responders did not follow such dynamics, suggestive of systemic dysregulation. Through multi-omics integration, we identified key metabolites and proteins and their likely role in immune response to vaccination. High pre-vaccination IL-15 concentrations negatively associated with antibody production, further supported by experimental validation in mice revealing an IL-15-driven NK-cell axis with a suppressing role on antibody production. Finally, we propose certain long-chain fatty acids as modulators of persistent inflammation in non-responders. Our findings highlight the potential for stratification of vaccinees and open avenues for possible pharmacological interventions to enhance vaccine responses.

Key words: Systems immunology, influenza vaccination, elderly, IL-15, NK cells, long-chain
 fatty acids, multi-omics integration

97 98 INTRODUCTION

99

100 Influenza epidemics are major public health threats, with more than 400,000 fatalities 101 estimated worldwide per year, mostly among the elderly<sup>1</sup>. Inactivated subunit influenza 102 vaccination has proven to be the best preventive and cost-effective approach for inducing 103 protective immune memory<sup>2,3</sup>. However, many factors, particularly old age, have been 104 strongly associated with a reduced protection despite vaccination<sup>4,5</sup>. Consequently, the 105 elderly population is more vulnerable to influenza infection and influenza-associated 106 mortality<sup>1</sup>.

107

108 The inefficiency in generating protective immunity in the elderly has been attributed to the 109 ageing of the immune system, which is often characterised by lingering low-grade 110 inflammation and immunosenescence<sup>6</sup>. Our recent studies also showed that non-responders 111 are specifically characterized by multiple suppressive immune mechanisms affecting 112 regulatory T and B cells<sup>7</sup>. Earlier studies have also shown higher proportions of inflammatory 113 monocytes and cytotoxic NK cells in the elderly compared to the younger population, along with lower B cell responses<sup>8</sup> that were attributed to intrinsic defects in T and B cells. 114 Additionally, the elderly accumulate pro-inflammatory B cells that are unable to respond to 115 influenza vaccination<sup>9,10</sup>. At the molecular level, lower AP-1 activity along with enhanced 116 117 antiviral and interferon signalling in myeloid cells has been associated with a productive vaccination response<sup>11</sup>. Higher AP-1 activity induces activation of pro-inflammatory 118 cytokines, which may contribute towards a higher inflammatory status<sup>11,12</sup>. However, in the 119 younger population (< 50 years), pre-vaccination pro-inflammatory status driven through NF-120 121 kB signalling has been associated with high antibody response<sup>13</sup>. In addition to cytokines, metabolites may also serve as important regulators of immune responses<sup>14,15</sup>. Differences in 122 123 metabolite profiles between young and elderly individuals have been reported, along with 124 differential metabolic regulation of the immune response to vaccination<sup>16</sup>. Post-vaccination, 125 young high responders showed reduced concentrations of polyunsaturated fatty acids 126 (PUFAs), whereas cholesteryl esters accumulated more in elderly high responders<sup>16</sup>. Purine 127 metabolism and glycine, serine and threonine metabolism have also been associated with 128 the vaccine response<sup>16</sup>. Together, these studies have indicated complex and age-dependent 129 metabolic regulation of the antibody response to vaccination.

130

131 Here, we used a systems immunology approach to examine the differential responsiveness 132 to influenza vaccination within a previously well-established elderly cohort spanning two independent influenza seasons<sup>7,17-19</sup>. The transcriptional signatures of the highest and 133 134 lowest responders allowed us to identify a chronic inflammatory signature that is distinct from 135 the inflammatory signature supporting the vaccine response. We also show distinct changes 136 in the plasma proteome and metabolome abundance upon vaccination in high and low 137 responders. Furthermore, we identified pre-vaccination protein biomarkers associated with 138 poor vaccine response. Additionally, we identified pre-vaccination metabolites associated 139 with vaccine response, which may serve as potential modulators of the chronic inflammation 140 in the elderly. Taken together, these findings illustrate that an increased pro-inflammatory 141 profile is detrimental to influenza vaccine response in the elderly population. Results from 142 this study provide insight into the immunological processes driving differential 143 responsiveness to vaccination, and will open novel opportunities for improved vaccine

144 design as well as modulation of the immune system to enhance the vaccine response in the 145 elderly.

146 147

148 RESULTS

- 149
- 150

#### Demographic characteristics and their association to vaccine response in the elderly 151

152 We collected whole blood and plasma samples from 234 trivalent inactivated influenza 153 vaccine (TIV)-vaccinees aged 65 and above in Hannover, Germany across two influenza 154 seasons and generated a multimodal dataset covering whole blood transcriptome, plasma 155 proteome, plasma/serum metabolome, and serology from up to five time points (pre-156 vaccination, days one-three, six-seven, 21-35 and 60-70 post-vaccination). By doing this, 157 different stages of the vaccination response were covered (Figure 1A). Examining the 158 serological data, we observe heterogeneity across the elderly donors, with the majority of 159 donors showing sufficient antibody responses expected to confer protection. Donors were 160 evaluated based on their antibody fold change (day 35 vs pre-vaccination) against the three 161 strains included in the TIV vaccine', and categorised as Triple Responders (TR, >4-fold rise 162 in antibody titres against all three strains), Non Responders (NR, <4-fold rise in titres against 163 all three strains), or Other (>4-fold rise in titres against one or two of the vaccine strains; 164 Figure 1B). As we have access to data from two independent seasons, we used the larger 165 cohort (season 2015/2016, n=200) as a discovery cohort, and the smaller cohort to replicate 166 our findings (season 2014/2015, n=34).

167

168 We observed another layer of heterogeneity among donors based on pre-vaccination 169 antibody titres. Previous studies have discussed the impact of high pre-vaccination 170 hemagglutination inhibition (HAI) titres that lead to reduced antibody fold change upon vaccination<sup>8,20-22</sup>. Within our cohort, approximately one-third of the donors (H1N1:36%, 171 172 B:34%, H3N2:33%) followed this pattern. Nevertheless, the majority of responders in this 173 cohort (TRs and Others) still showed a high antibody response to vaccination that was 174 independent of pre-vaccination titres, suggesting that pre-vaccination titres are not the only 175 variable defining the vaccine response (Figure 1B). Consistent positive correlations among 176 antibody titres against the three influenza strains and positive correlations between HAI titres 177 and microneutralization (MN) titres per strain were observed (Supplementary Figure 1A-1B). 178 We did not observe statistically significant differences in serological responses between 179 elderly males and females (Supplemental Figure 1C). Across two seasons, we observed a 180 significant negative correlation of antibody titres with age for the H1N1 strain, but not for the 181 H3N2 and B strains (Supplementary Figure 1D). These observed patterns were replicated in 182 the smaller cohort.

- 183
- 184
- 185 186

# Distinct transcriptional signatures between elderly triple and non-responders

187 We first evaluated transcriptome data generated from the 10 highest (TRs) and 10 lowest 188 (NRs) responders to identify transcriptional differences between the groups and the 189 transcriptomic dynamics of vaccine response resulting in 1466 significantly differentially 190 expressed genes (DEGs) (adj. p-value < 0.01, Figure 1C). Functional significance of the 191 differential transcriptome profiles between TRs and NRs (independent of time) was identified

using gene set enrichment analysis (GSEA) with blood transcriptome modules (BTMs)<sup>23</sup> as 192 193 background (Supplementary Data 1). We found that the top 40 most significantly enriched 194 modules showed a consistent upregulation of T and B cell related, and T cell activation 195 modules in TRs, whereas NRs showed upregulation of inflammatory and inflammatory 196 signalling modules (Figure 1D). These pathways were consistently upregulated in TRs and 197 NRs at all time points, including pre-vaccination. These differences were also reflected by 198 different proportions of immune cell populations in these donors using transcriptome 199 deconvolution (CIBERSORT<sup>24</sup>, Figure 1E and Supplementary Figure 2A). In line with our 200 enrichment results, we found that TRs had higher proportions of T and B cells, whereas NRs 201 showed elevated proportions of neutrophils. These results agree with reported flow 202 cytometry results<sup>7</sup> and with the observed trend of higher neutrophils in NRs at the pre-203 vaccination time point (Supplementary Figure 2B). Despite enrichment of monocyte-related 204 BTMs in NRs, we did not observe differences in monocyte proportions between TRs and 205 NRs in deconvolution or cell blood counts. This suggests higher activity of monocytes in NRs 206 irrespective of cell proportions (Figure 1E and Supplementary Figure 2B).

207

208 We next evaluated the pre-vaccination BTMs alone that separate TRs from NRs. We found 209 TRs showed enrichment for T cell activation and signalling, Th2 differentiation and plasma/B 210 cell modules (Figure 2A, Supplementary Data 2). A recent study described a high 211 inflammatory pre-vaccination endotype that is predictive of high vaccine responders in adults, but not in the elderly<sup>13</sup>. In line with these results, we did not observe enrichment of 212 213 inflammatory BTMs at the pre-vaccination time point in TRs. Instead, we observed an 214 opposite pattern, in which TRs had lower enrichment of inflammatory modules compared to 215 NRs (Supplementary Figure 3A). When we evaluated the expression patterns of the genes 216 enriched in these pathways, we found only CD83 and IL23A to be significantly upregulated 217 in TRs at all time points, suggesting that only select genes are important in elderly TRs and 218 support the immune response (Supplementary Figure 3B). While we observed a gene 219 expression pattern associated with cells engaged in humoral responses in TRs (which is in 220 line with their high responsiveness to vaccination), the NRs presented a consistently 221 upregulated inflammatory signature.

222 223

## 224 *Major differences in post-vaccine transcriptional dynamics between elderly triple and* 225 *non-responders*

226 227 We then assessed transcriptional changes resulting from vaccination over time, in each 228 group separately. Based on significant DEGs at each time point compared to pre-229 vaccination, we observed distinct post-vaccination dynamics between TRs and NRs. TRs 230 showed an early response at three days post-vaccination, evident from a small proportion of 231 DEGs, followed by the highest change in gene expression at day seven before going back to 232 pre-vaccination gene expression levels. However, NRs did not show significant DEGs at any 233 time point post-vaccination compared to pre-vaccination (Figure 2B and Supplementary 234 Figure 3C). Interestingly, ~18% of genes significantly upregulated at day three in TRs were 235 also significantly upregulated in NRs at all time points (Figure 1C and 2C). Functionally, the 236 day three transcriptomic profile was enriched in innate immune modules related to antiviral, 237 interferon and complement activation (Supplementary Figure 3D, Supplementary Data 3). 238 Consequently, the upregulated inflammatory genes in NRs were categorised in two clusters 239 depending on their expression patterns: "Transiently up day 3 TRs" or "Consistently up NRs"

240 (Figure 1C and 2C). While "Transiently up day 3 TRs" genes were involved in antiviral 241 response, the "Consistently up NRs" genes were enriched for modules related to AP-1 242 transcriptional network, neutrophils and other inflammatory signalling modules, which may 243 suggest a chronic inflammatory status in NRs (Figure 1C, 2D). These results highlight that 244 TRs mounted an immune response evident from transcriptional changes at different time 245 points (percentage of DEGs at day three and day seven) post-vaccination. However, NRs 246 maintained an inflammatory profile at all time points, which in turn may impede mounting the 247 vaccine response.

- 248
- 249

# Elderly non-responders show higher activation of NK cells seven days post vaccination.

252

253 We next examined day seven transcriptional changes in TRs and NRs separately in greater 254 detail, as day seven showed the highest change in gene expression in TRs compared to pre-255 vaccination (Figure 2B). GSEA results in TRs showed strong positive enrichment of multiple 256 modules particularly related to cell cycle, plasma cells, immunoglobulins and T cell 257 activation, among others. Even though NRs did not show statistically significant DEGs seven 258 days post vaccination compared to pre-vaccination, GSEA at this time point showed very 259 few enrichments related to cell cycle, T cell activation and plasma cells. However, the 260 inflammatory modules were downregulated in both groups compared to pre-vaccination 261 (Supplementary Figure 3E, Supplementary Data 3).

262

263 We associated the enriched modules with cell proportions identified through transcriptome 264 deconvolution. Cell cycle modules were strongly associated with plasma cells in TRs (FDR < 265 0.05) suggesting clonal expansion of plasma cells, whereas cell cycle modules in NRs did 266 not show significant associations with any cell subsets (Figure 2E, left). Transcriptional 267 changes, particularly in plasma cells and B cells seven days post vaccination have also been shown through single-cell studies<sup>25</sup>. Plasma cell proportions transiently increased at this time 268 269 point for TRs, whereas this was not seen in NRs (Figure 1E). This observation is supported 270 by previous studies which showed that an increase in antibody secreting cells at day seven correlates positively with high antibody fold change<sup>26</sup>. Instead, activation modules were 271 272 strongly positively associated with NK and CD8 T cells in NRs. We also observed similar 273 associations in TRs, but they were weaker than in NRs (Figure 2E). The deconvolution 274 results also show higher proportions of activated NK cells in NRs (Figure 1E). Flow 275 cytometry on donors from the replication cohort also confirmed these findings 276 (Supplementary Figure 4). A higher proportion of NK cells in NRs compared to TRs has also 277 been reported in the single-cell dataset<sup>7</sup>. Increased NK cell proportions and activity in the elderly compared to younger adults has been previously reported<sup>8</sup>. In addition, a significant 278 279 negative association of neutrophils with T cell activation BTMs in NRs suggests modulation 280 of T cell activation by neutrophils. Finally, in NRs, Tregs were negatively associated with 281 immune activation BTM, which may suggest attempts at suppression of inflammation in 282 response to vaccination. Altogether, the observed associations link cell subsets to the 283 functional changes characterised through BTMs and highlight multiple differences in TRs 284 and NRs post-vaccination. Particularly, we observe higher NK cell proportions and higher 285 activation of NK cells as a characteristic of the elderly NRs.

# 288Post-vaccination plasma proteome and metabolome differences between triple and289non-responders highlight key molecules involved in vaccination response

290

291 We next evaluated the proteome (Olink-Explore 384 panel) profile between all TRs (n=71) 292 and NRs (n=10) in our cohort, measuring up to 311 proteins. Differential abundance testing 293 between TRs and NRs irrespective of time showed higher CLEC7A in TRs in the discovery 294 cohort (adj. p = 0.03, moderated t-test,), but not in the replication cohort possibly because of 295 the small effect size (Supplementary Figure 5A, 5B). We next examined protein dynamics 296 induced by vaccination separately in TRs and NRs by comparing each time point to pre-297 vaccination. Unlike the distinct dynamics observed at the transcriptome level in TRs and 298 NRs, changes in protein abundance in both TRs and NRs seven days post-vaccination were 299 observed (Figure 3A, Supplementary Data 4). In TRs, 14 proteins were upregulated at seven 300 days post-vaccination (Figure 3B), among which TNFRSF13B (also known as TACI) has been widely described for its role in B cell proliferation and plasma cell differentiation<sup>20,27,28</sup>. 301 Other proteins upregulated in TRs include IFNLR1<sup>29,30</sup>, a receptor for type three interferons; 302 303 CCL3<sup>31</sup> or MIP1a, CD48 and SLAMF7. TNFRSF13B, IFNLR1 and CCL3 also showed a 304 trend of increased abundance in the replication cohort at day seven post-vaccination 305 (Supplementary Figure 5B). On the other hand, five distinct proteins were upregulated in 306 NRs at day seven post-vaccination, including PARP1, EGLN1 and SERPINB8. PARP1 plays a role in oxidative stress-induced inflammation<sup>32</sup> and also in recruiting NK cells in a viral 307 response<sup>33</sup>. EGLN1/PHD2 and SERPINB8 are involved in anti-inflammatory roles<sup>34,35</sup>. At day 308 309 35, we found relatively fewer changes (Supplementary Figure 5C). Altogether, differences in 310 plasma proteome dynamics in TRs and NRs highlights the differential response to 311 vaccination induced in the two groups.

312

313 We also assessed untargeted metabolomic data measured by liquid chromatography-gas 314 spectrometry (LC-MS) and focused specifically on 192 endogenous metabolites (see 315 Methods). No significant differentially abundant metabolites between TRs and NRs were 316 found, irrespective of the time points. However, metabolites in TRs showed significant 317 changes at day seven and 35 compared to pre-vaccination, whereas this was less evident in 318 NRs (Figure 3C top, Supplementary Data 5). Summarising the metabolites into taxonomic 319 classes, TRs showed significant increased abundance of organic acids, particularly amino 320 acids, crucial for adequate immune function both at seven and 35 days post-vaccination<sup>14</sup>. 321 On the other hand, metabolites with reduced abundance both at seven and 35 days post-322 vaccination were lipids and lipid-like molecules, more specifically fatty acyls (Figure 3C 323 bottom, Supplementary Figure 5D, 5F). These findings were validated in the replication 324 cohort, suggesting that overlapping metabolic signatures were induced by vaccination in 325 both seasons (Supplementary Figure 5E). Interestingly, four out of five upregulated lipids 326 and lipid-like molecules in TRs are bile acids. Bile acid perturbation has been described in antibiotics-treated donors with low antibody response to vaccination<sup>12</sup>. In contrast, NRs did 327 328 not show any significant differences in metabolite abundance seven days post-vaccination, 329 but instead showed a decrease in lipid abundance 35 days post-vaccination (Figure 3C top 330 and bottom). Pathway over-representation analysis in TRs at day seven showed significant 331 upregulation of metabolic pathways involving amino acid, glycine/serine metabolism and 332 glucose homeostasis (Figure 3E, Supplementary Data 6). On the other hand, downregulated 333 metabolic pathways were related to fatty acids, linoleic acid metabolism and signal 334 transduction, among others. In summary, the increased and sustained abundance of amino

acids with reduced abundance of fatty acyls over time suggests the importance of thesemetabolite classes in vaccine response.

337

338 Furthermore, we integrated plasma molecules upregulated at day seven with transcriptome 339 BTMs to derive their functional significance. In TRs, protein concentrations of TNFRSF13B 340 and IFNLR1 were strongly positively associated with B cells and plasma cell immunoglobulin 341 modules from transcriptome (False Discovery Rate (FDR) <0.05). The CCL3, GZMA and 342 CD48 protein concentrations were also significantly positively associated with T cell 343 transcriptional modules, suggesting their role in the activation of T cells. Among metabolites, 344 uridine and tyrosine also showed positive associations with T cell activation and plasma cell 345 numbers, which may imply their involvement in mounting the immune response. Uridine has 346 previously been shown to be important for T cell proliferation<sup>36</sup>. Beta-alanine, lactic acid and 347 serine all positively correlated with NK cells (Figure 3F). In contrast, no significant 348 associations between the proteome and transcriptional modules were found in NRs. 349 However, EGLN/PHD2, SERPINB8 and NBN were negatively associated with inflammatory 350 pathways (nominal p-value < 0.05, Supplementary Figure 6). Combining these results, we 351 show distinct changes in the proteome and metabolome following vaccination and describe 352 their potential significance in shaping the vaccination response in the elderly vaccine 353 responders.

354 355

### 356 *Multi-omics integration reveals a common axis of variation across layers separating* 357 *high and low responders*

358

359 Next, we integrated the three omics layers of the highest (TRs, n=10) and lowest responders 360 (NRs, n=10) to examine the interconnected processes underlying the heterogeneous 361 influenza vaccine response in the elderly. Using multi-omics factor analysis (MOFA)<sup>37</sup>, an 362 unsupervised method, 15 latent factors were identified which explained different levels of data variation along with varying contributions of omics layers within each latent factor 363 364 (Figure 4A). Among these, factor three showed a common axis of variation among three 365 omics layers that separated TRs from NRs irrespective of time (Figure 4B). Examining 366 significance of the other factors showed that factors four and six were consistent with the 367 time dynamics differences observed in TRs and NRs (Supplementary Figure 7A). 368

369 To examine the significance of this common axis (latent factor three), we examined the top 370 proteins and metabolites identified through this factor (Figure 4C) and evaluated these in all 371 TRs (n=71) and NRs (n=10). Among the proteins, CCL25 and CCL3 were consistently more 372 abundant in TRs than in NRs. Similarly, for metabolites, the amino acids arginine and 373 methionine were more abundant in TRs (Figure 4D and Supplementary Figure 7B). To 374 further assess the significance of these amino acids in immune function, we examined the 375 association of amino acids with cytokine production capacity, particularly induced upon influenza stimulation in an independent cohort of 500 healthy individuals<sup>38,39</sup>. Arginine and 376 methionine showed significant positive associations with IL1β, IL6 and TNF (Figure 4E, 377 378 Supplementary Figure 7C). The increased abundance of these amino acids in TRs and their 379 positive association to pro-inflammatory cytokine production may indicate their involvement 380 in shaping the adaptive immune response to influenza vaccination via modulation of cytokine 381 production.

383 Finally, we then created a network of significant intra- and inter-omic connections by 384 associating plasma molecules with transcriptome BTMs (Methods), overlaying the weights 385 assigned for TRs (red) and NRs (blue) from MOFA latent factor three (Figure 4E). Across 386 omic layers, the transcriptome and proteome were highly connected, whereas the 387 metabolome was less connected to the other two layers. The metabolite arginine was 388 positively associated with TR-related BTMs involving plasma cells and immunoglobulins. 389 Similarly, xanthosine was positively associated with immune activation BTMs, which was 390 estimated as a predictor for NRs. Both xanthosine and orotidine are involved in nucleotide metabolism which plays an important role in inflammation<sup>40,41</sup>. We also observed strong 391 392 positive associations of glyceric acid 1,3-bisphosphate/1,3-BPG with up to seven proteins 393 that are predictors for NRs. In summary, we describe a common axis of variation in 394 transcriptome, proteome and metabolome which highlights the interconnected differences in 395 influenza vaccine response between elderly TRs and NRs.

396 397

400

# 398 Pre-vaccination high plasma IL-15 concentration negatively correlates with antibody 399 response

401 One of the prerequisites for complete protection is the ability to produce sufficient antibodies 402 against all three strains of the influenza vaccine. To prioritise the important pre-vaccination 403 plasma proteins for antibody response to three strains of influenza vaccine concurrently, we 404 used partial least square regression (PLSR) in 200 donors (discovery cohort). This allowed 405 us to perform a systematic investigation of heterogeneity at the pre-vaccination time point. 406 The resulting proteins from the top three PLSR components explain ~40% variance of the 407 antibody fold change within the cohort (Figure 5A). We evaluated the top 30 proteins from 408 each of the three components to examine the directionality of the association with antibody 409 response per strain (Figure 5B). Overall, the majority of the prioritised proteins showed 410 contrasting associations with the three strains. Interestingly, TNFSF13/APRIL and IL-15 411 were negatively associated with antibody fold changes for all three strains (Figure 5B,5C and Supplementary Figure 8A left). Both these proteins have been described as pro-412 413 inflammatory cytokines and in the pathogenesis of influenza infection<sup>42-44</sup>. In the replication 414 cohort, we also found IL-15 negatively associated with high antibody changes for two strains, 415 whereas this was not true for TNFSF13, perhaps due to the small effect size that is hard to 416 replicate in a smaller cohort (Supplementary Figure 8A right, 8B). Single-cell RNA 417 sequencing on human PBMCs showed that IL-15 is mainly expressed by monocytes<sup>45</sup> 418 (Supplementary Figure 8C). Based on these results, the contrasting relationship of the 419 majority of prioritised proteins against the three strains suggests a complex relationship of 420 these proteins involved in providing complete protection against influenza infection. 421 However, the consistent negative association of IL-15 with antibody response in both the 422 discovery and replication cohort suggests a detrimental role in protection against influenza.

423 424

# High IL-15 concentration leads to reduced antibody titres through NK cells mediated suppression of germinal centre responses

427

428 IL-15 is important for NK cell proliferation and maturation<sup>46–48</sup>. From both bulk and previously 429 reported single-cell transcriptomics<sup>7</sup>, we observed higher frequencies of activated NK cells 430 and total NK cell numbers in NRs (Figure 1E). NK cells have been described to suppress

germinal centre (GC) responses<sup>49,50</sup>. We therefore examined the impact of a perturbation of 431 432 the IL-15-NK cell axis on antibody production with IL15RA-deficient mice. We immunised 433 IL15RA+/+ and IL15RA-/- mice with ovalbumin (OVA-IFA or OVA-Alum) to examine the 434 resulting humoral response 11 days post-immunization, at the time of maximum GCresponse in this animal model<sup>51</sup> (Figure 5D). *IL15RA<sup>-/-</sup>* mice showed a marked reduction of 435 436 NK cells in the spleen (as anticipated, given the importance of IL-15 for NK cell numbers), 437 without significant differences on B cell populations, but with slight differences on the 438 frequency of CD4+ and CD8+ T cells (a population that can also be affected by IL-15 439 reduction) (Figure 5E, Supplementary Figure 9A). In the draining lymph node, we observed a consistent increase of Tfh cells and a decrease of Treg and Tfr cells in IL15RA<sup>-/-</sup> mice, 440 441 although without reaching statistical significance (p-values > 0.05) (Supplementary Figure 9B). However, the Tfh/Tfr ratio, critical in the regulation of GC responses<sup>52</sup>, was significantly 442 higher in  $IL15RA^{-L}$  mice (p-value = 0.02, Wilcoxon ranked sum-test, Figure 5F). In the same 443 mice that had an increased Tfh/Tfr ratio, we observed higher production of antibodies, 444 445 across two different immunisation protocols (p-values = 0.006 (OVA-Alum) and 0.048 (OVA-446 IFA), Wilcoxon ranked-sum test, Figure 5G-H). In conclusion, these results suggest that the 447 reduction of IL-15 and NK cells led to more effective antibody production, in line with the 448 data from elderly NRs who displayed higher IL-15 and NK cell activation together with poor 449 antibody response (Figure 5I).

450 451

# 452 *Pre-vaccination plasma malic and citric acid concentrations negatively correlate with* 453 *antibody response*

454

455 To evaluate the pre-vaccination metabolite levels with antibody responses against three 456 strains, PLSR was used in a similar way as described above. Herein, the metabolites in the 457 top eight PLSR components explain ~40% variation of the antibody fold change among 458 donors suggesting high inter-individual variation in the donors as a consequence of 459 metabolic differences (Figure 6A). Metabolites prioritised in the first component showed 460 malic acid and citric acid as top molecules, with negative associations to antibody response 461 (Figure 6B, 6C and Supplementary Figure 9A). To derive the role of citric acid and malic acid 462 in immune function, we associated pre-vaccination abundance of these metabolites with 463 deeply phenotyped immune cell counts and cytokine production induced upon influenza 464 stimulation in two independent cohorts of 300 and 500 healthy individuals, respectively<sup>38,39,53,54</sup>. 465 Citric showed acid significant negative associations with 466 CD4+CCR6+CCR5+CCR7+ T cells along with three different subsets of immature 467 neutrophils (FDR<0.05) (Supplementary Figure 9B). Malic acid showed strong negative 468 associations with TNF  $\Box$ , IL6 and IL1 $\beta$  cytokine levels upon influenza stimulation (Figure 6D). 469 Furthermore, we found betaine and cysteine as the top predictors from components one and 470 two, respectively, to be consistently positively associated with antibody response across all 471 strains (Figure 6B and Supplementary Figure 9C). Betaine has been described for its inhibition of IL1ß production and release<sup>55,56</sup> and for its suppression of pro-inflammatory 472 473 signalling during ageing<sup>57</sup>. These results reflect the impact of pre-vaccination metabolite 474 abundance linked to different physiological immune states across responders culminating in 475 differential vaccination response in the elderly.

- 476
- 477

# 478 Unsaturated long chain fatty acids are negatively associated with pre-vaccination IL479 15 abundance

Given the putative role of high IL-15 in suppressing antibody production in the elderly, we evaluated the relationship of pre-vaccination IL-15 abundance and metabolites. Pre-vaccination IL-15 showed strong negative associations with odd-chain (pentadecanoic acid) and certain unsaturated long-chain fatty acids (LCFAs, e.g. palmitoleic acid) (p value < 0.02) (Figure 6F and Supplementary Figure 9D). These LCFAs were also among the top 30 predictors for PLSR component two, explaining variation in antibody fold change among the donors (Figure 6E and 6F). LCFAs and especially poly-unsaturated fatty acids have been described as important immunomodulatory metabolites to protect against infections<sup>58</sup>. To test the significance particularly of LCFAs in suppressing inflammatory proteins, the relationship of all pre-vaccination lipid and lipid-like molecules (taxonomy class) with these proteins was examined. LCFAs were negatively associated with inflammatory proteins, whereas other lipid molecules showed both positive and negative associations (Supplementary Figure 9E). We also examined the role of LCFA in a younger cohort (500FG<sup>38,39</sup>, with 98% donors less than 65 years of age), however, the LCFA-specific negative associations with inflammatory proteins were absent (Supplementary Figure 9E). Among the LCFAs, the most significantly negatively associated metabolite was pentadecanoic acid, an odd-chain fatty acid with anti-inflammatory properties and resistance to oxidation<sup>59,60</sup>. Taken together, the data suggests an age-dependent role of LCFAs in the control of inflammation. We described different metabolites associated with IL-15 and other inflammatory proteins, as well as the antibody fold change, suggesting their role in modulating the vaccine response in the elderly, particularly LCFAs as potential pre-vaccination suppressors of high inflammation.

526 527

539 DISCUSSION

540

538

In this work, we evaluated a large cohort of healthy elderly individuals to understand the
heterogeneity of influenza vaccination response, specifically to address two main questions:
1) How does the vaccination response differ between responders and non-responders, and
2) Which pre-vaccination biomarkers correlate with the vaccination response. To answer
these questions, we examined the transcriptome, proteome and untargeted metabolome of
these donors separately, as well as across omics layers.

547

548 In the transcriptome, proteome, and metabolome layers, we observed post-vaccination 549 dynamics that were indicative of mounting of an immune response to vaccination in TRs 550 whereas, as expected, these dynamics were absent or altered in NRs. NRs were instead 551 characterised by increased and activated NK cell populations and persistent inflammation. In 552 line with these findings, the NK cell receptor KLRB1 was shown as a negative predictor for 553 vaccine response in the elderly<sup>21</sup>, whereas *NKG2C* expression was reported as positively correlated with influenza vaccination<sup>61</sup> in healthy individuals. This opposing observation of 554 555 NK cells may be related to the ageing immune system. Signalling through inflammatory 556 molecules is important for mounting an immune response, while persistent low-grade 557 inflammation, termed 'inflammaging', can result in exhaustion and is detrimental to the vaccine response<sup>62,63</sup>. In NRs, evidence from the transcriptome suggests persistent 558 559 inflammation driven through AP-1 transcriptional networks, among others. On the other 560 hand, the post-vaccination proteins consist of proteins with anti-inflammatory roles. These 561 opposing findings from the different layers may suggest a dysregulation where NRs are 562 attempting to suppress the inflammation resulting from vaccination required for mounting the 563 necessary immune response. A recent study has revealed endotypes predictive of antibody 564 response to vaccination across different vaccines, including influenza<sup>13</sup>. However, this 565 endotype was not identified in elderly (>50 years) individuals. Our study extends these 566 findings in the elderly and defines the pre-vaccination transcriptome profile separating high 567 and low responders, with adaptive immune modules enriched in high responders. This 568 suggests that a high persistent inflammatory status predictive of high responders in the 569 young is increasingly detrimental with age.

570

571 Using multi-omics integration for day seven and across time points, we were able to find key 572 molecules that are important in supporting and leading to a productive vaccine response. 573 Interestingly, some of these identified molecules e.g. CCL25, CCL3 and arginine have

574 already been studied as potential immune-adjuvants in vaccination and/or as supplementation for a better humoral response to vaccination<sup>31,63-65</sup>. CCL25, a chemokine 575 576 ligand for CCR9 has been shown to play both pro and anti-inflammatory roles in various 577 diseases<sup>66</sup>. CCL3 and its receptor CCR5 have been implicated in leukocyte recruitment into the airway leading to upregulation of antiviral responses in influenza infection<sup>67</sup>. Amino acids 578 in general are crucial for immune function<sup>14,15</sup>. In fact, we observed consistent upregulation 579 580 of amino acids post-vaccination in TRs, but not in NRs. In this study, we showed functional 581 associations of plasma concentrations of metabolites arginine and methionine to cytokine 582 production upon influenza stimulation using an independent cohort. The upregulation of 583 these amino acids in TRs irrespective of vaccination and the role of these molecules in 584 cytokine production suggests an important role in protective immunity and consequently 585 markers of protection in elderly TRs. In summary, we indicate biomarkers that support both a 586 robust immune response to influenza stimulation and the vaccine response.

587

588 Pre-vaccination plasma IL-15, malic acid, and citric acid concentrations are negatively 589 associated with antibody response. We propose a model where high abundance of pre-590 vaccination IL-15 leads to increased activated NK cells, which in turn inhibit the GCs to 591 suppress antibody production (Figure 6F). Modulation of adaptive immune responses 592 through NK cells has been proposed for better vaccine design, where NK cells control the magnitude and quality of immune response<sup>68–70</sup>. Previous work and our current results have 593 594 shown lower levels of T and B cells in NRs compared to TRs<sup>7</sup>. The simultaneous decrease 595 of T and B cells, with increased NK cell proportions may further cause the suppression of 596 antibody responses in NRs. Monocytes are the main source of IL-15 in immune cell 597 populations in human blood and are reported to produce more IL-15 with increasing age<sup>71</sup>. 598 We did not observe higher monocyte proportions but higher monocyte (inflammatory) 599 transcriptional activity in NRs. IL-15 has also been described to inhibit apoptosis of neutrophils<sup>72</sup>, which were more abundant in our NRs. 600

601

602 Together, these findings suggest contributions from inflammatory monocytes and neutrophils 603 in maintaining a persistent inflammatory milieu in NRs. The receptor for IL-15 is also 604 expressed by dendritic cells and the importance of the cross-talk between NK cells and 605 dendritic cells in immune cell activation and maturation has been established<sup>73</sup>. We did not 606 observe differences in deconvoluted dendritic cell proportions between TRs and NRs. 607 However, cross-talk between these cell subsets within the secondary lymphoid tissues could 608 play a role during influenza infection and its role in vaccination in the elderly is of interest for 609 future research. The top predictors from the metabolome PLSR component two consisted of 610 methionine and fatty acids, particularly unsaturated LCFAs. Methionine was one of the top 611 predictors for TRs picked by MOFA, as well as one of the top metabolites upregulated at day 612 seven post vaccination in TRs. Interestingly, unsaturated LCFAs were all negatively 613 associated with IL-15. Recent work has highlighted the role of fatty acid metabolism in the IgG1 response to influenza<sup>12</sup>. In line with this, we observed consistent downregulation of 614 615 fatty acyls in TRs post-vaccination, whereas this only occurred in NRs at the later time point 616 (day 35). These findings suggest a multifaceted role of fatty acyls by serving as energy 617 molecules and/or signalling molecules, thereby modulating the immune response. 618 Metabolites with known anti-inflammatory properties such as (poly)-unsaturated LCFAs and 619 odd-chain fatty acids could alleviate the chronic inflammation, leading to a more productive 620 vaccination response in the elderly.

We also need to acknowledge the limitations of this study. Larger cohorts are required in future studies to fully explore the molecular mechanisms leading to a protective or detrimental vaccine response. This includes examining the role of genetics in interindividual variation, the host microbiome and its interactions with the metabolome. The role of comorbidities frequently observed in the elderly (type 2 diabetes, cardiovascular diseases, etc.) may also affect the response to vaccination. Indeed, we found that a history of diabetes or herpes zoster (shingles) were independent risk factors for a poor humoral immune response to the H1N1 vaccine antigen in this study cohort<sup>19</sup>. Furthermore, it was recently identified in a study of responsiveness to COVID-19 vaccination that comorbidities, such as diabetes, are associated with a pro-inflammatory response and reduced vaccine responsiveness<sup>74,75</sup>. Although "inflammaging" associated with pro-inflammatory cytokines is also emerging as a common feature of poor vaccine responsiveness in people with chronic diseases and old age, it will be critical to understand the potential universal character of the identified mechanisms and biomarkers by performing studies using other vaccines and populations. Therefore, future studies incorporating these factors will provide an improved understanding of the vaccine response in the elderly. Furthermore, in vivo experiments and clinical trials are required to assess whether modulation of metabolites can improve the vaccine response in (elderly) non-responders.

670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 **ACKNOWLEDGEMENTS & FUNDING** 685 686 The authors thank all the participants in this study. We thank the Research Core Unit 687 688 689

Metabolomics of the Hannover Medical School for supporting the targeted metabolomics measurements. This work was supported by an ERC starting Grant (948207), a Radboud University Medical Centre Hypatia Grant (2018) and the Deutsche Forschungsgemeinschaft 690 (DFG; German Research Foundation) under Germany's Excellence Strategy - EXC 2155 691 project number 390874280 to YL and iMed, the Helmholtz Association's Cross Programme 692 Initiative on Personalized Medicine, to CAG and FP. C-JX was supported by a Helmholtz 693 Initiative and Networking Fund (1800167). MGN was supported by an ERC Advanced Grant 694 (833247) and a Spinoza Grant of the Netherlands Organization for Scientific Research. LG 695 research was supported by grants HR22-00741 ("la Caixa" Foundation), and 696 2022.04903.PTDC (Fundação para a Ciência e Tecnologia Portugal). This project was also 697 partly supported by the European Union's Horizon 2020 research and innovation programme 698 under the Marie Sklodowska-Curie grant agreement No. 955321

#### 699

#### 700 AUTHOR CONTRIBUTIONS

701

#### 702 Conceptualization and study design: YL

- 703 Sample collection: ST, PR, FP, CAG
- 704 Sample preparation: LZ, AA
- 705 Data analysis and investigation: SK, MZ, NN.
- 706 Murine experiments: RP, LG
- 707 Discussion and interpretation: SK, MZ, ST, PR, JBB, CJX, LABJ, MGN, LG, CAG, FP, YL
- 708 Writing original manuscript: SK, MZ, JBB, CJX, YL
- 709 Reviewing and editing manuscript: All authors.
- 710

#### 711 DECLARATION OF INTERESTS

- 712
- 713 The authors declare no competing interests
- 714
- 715 DATA AND CODE AVAILABILITY
- 716

717 Raw data and code will be made available upon publication. Datasets are fully available for

- 718 reviewers.
- 719
- 720
- 721
- 121
- 722
- 723
- 724
- 725
- 726
- 727
- 728
- 729
- 730
- 731
- 732

#### 733 FIGURE LEGENDS

734

735 Figure 1. Influenza vaccination cohort overview and transcriptome of highest and lowest 736 responders. (A). Overview of the different omics datasets generated in this study. We 737 generated multi-modal datasets covering the transcriptome, proteome and metabolome 738 response to influenza vaccination from up to 234 individuals for different timepoints spanning 739 both pre and post-vaccination, covering two independent seasons of influenza vaccination. The serological data is adapted from earlier publications on the same cohort<sup>7,17</sup> (B). Circos 740 741 plot showing the serological response to trivalent inactivated influenza vaccine (TIV). Each 742 heatmap depicts pre-vaccination antibody titres against the particular strains included in the 743 vaccine (H3N2, H1N1, B), whereas the corresponding histograms show the log2 fold-change 744 in antibody titres against the strains upon vaccination. Donors were classified as TR, NR or 745 Other based on their serological response (outer tiles). (C) Heatmap showing mean gene 746 expression levels across 10 TRs and 10 NRs for each time point. Each row is a gene that is 747 significantly differentially expressed between TRs and NRs, with purple indicating higher 748 gene expression levels and green indicating lower gene expression levels (adj. p-value < 749 0.01). (D) Top 40 BTMs listed based on gene set enrichment analysis (GSEA) of genes that 750 are differentially expressed between TRs and NRs. Positive (red) normalised enrichment 751 scores (NES) correspond to BTMs upregulated in TRs, whereas negative NES corresponds 752 to BTMs upregulated in NRs. (E) Line plots depicting immune cell population proportions for 753 all timepoints as estimated by CIBERSORT, stratified for TRs and NRs. Each dot is a 754 sample coloured for TRs (red) or NRs (blue).

755

756 Figure 2. Low inflammatory status at pre-vaccination stage indicator of high responders. (A) 757 BTMs significantly upregulated in TRs at the pre-vaccination timepoint. Boxplots show 758 median with interguartile range and Tukey whiskers. (B) Line plot summarising changing 759 gene expression in TRs (red) and NRs (blue) upon vaccination indicated by the percentage 760 of significantly differentially expressed genes over time compared to pre-vaccination. (C) 761 Line plots for two clusters of genes, where the cluster "Transient day 3 TRs" contains genes 762 upregulated in TRs at day 3 post-vaccination. Genes in the cluster "consistent up NRs" are 763 upregulated in NRs at all timepoints. Each dot represents the mean of genes per donor for 764 each cluster, line plot stratified for TR and NRs. (D) Mean expression of genes for significant

765 BTMs and HALLMARK pathways clustered shows split based on transient upregulation in 766 TRs (top) and downregulation in TRs at all time points (bottom). (E) Association of 767 CIBERSORT cell proportions with cell cycle BTMs (left) and cell type signature BTMs (right) 768 at seven days post-vaccination. Size of the dots represent adjusted p-values from linear 769 mixed models, whereas colour represents the estimate from the model. Associations with 770 adjusted p-values < 0.05 plotted, for TRs, while all associations for NRs with cell cycle BTMs 771 only irrespective of adjusted p-value threshold (grey). Associations with adj. p-value < 0.05 772 for cell type signature BTMs for NRs shown.

773

774 Figure 3 Plasma proteins and metabolite changes upon vaccination are distinct in TRs and 775 NRs. (A) Line plot showing significant changes (padj < 0.05) in protein abundance in TRs (N 776 = 71) and NRs (N=10) post-vaccination. TRs show a higher percentage of significantly 777 regulated proteins, while NRs show a comparably dampened response. (B) Volcano plot of 778 proteins upregulated in TRs and NRs 7 days post vaccination with significant proteins 779 coloured in red and labelled; Proteins were considered significant at adj. p-value < 0.05 (C) 780 Line plot showing significant changes in metabolite abundance in TRs (N=71) and NRs 781 (N=10) post vaccination. (D) Significantly differentially regulated metabolites categorised based on their taxonomic class as annotated by the Human Metabolome Database (HMDB). 782 783 The upper and lower parts of the bars represent up- and down regulated metabolites, 784 respectively. The "Measured" column represents the total universe of metabolites that we 785 considered (192 endogenous metabolites, see Methods). The TR and NR columns indicate 786 significantly regulated metabolites at each timepoint compared to day 0. (E) Pathways 787 enriched for metabolites with increased or decreased abundance 7 days post vaccination in 788 TRs. Enrichment of pathways was calculated using IMPALA. Pathways with adj. p-value < 789 0.05 are shown. (F) Integration of proteins and metabolites with increased abundance at 7 790 days post vaccination with transcriptome pathways in TRs. Linear mixed models were used 791 to estimate the association between protein / metabolite abundance and mean 792 transcriptomic pathway activity (Methods). Drawn links are significant with adj. p-value < 793 0.05. Colour and width for the links are based on p-values, where wide red links indicate 794 increased significance.

795

796 Figure 4 Multiomics integration of high and low responders (A) Bar plot showing the 797 proportion of explained variance per factor resulting from unsupervised factor analysis 798 method MOFA. Colours within each bar indicate the contribution of each modality. (B) MOFA 799 Factor 3 separates TRs from NRs irrespective of time and across modalities. Y-axis 800 represents the Factor 3 variance value attributed to each donor. P-values are generated 801 using a Wilcoxon ranked-sum test. (C) Top most positive and negative molecules within the 802 metabolome and proteome modalities as calculated by MOFA. Molecules are ranked on 803 MOFA scaled weights for factor 3. Positive weights are for TRs, whereas negative weights 804 correspond to NRs. (D) Abundance of CCL25 and L- arginine in all 81 TR and NRs. P-values 805 are generated using a Wilcoxon ranked-sum test. (E) Association of arginine with cytokine 806 response post influenza stimulation in 500 FG cohorts. P-values are generated using t-test. 807 Partial correlation estimate was calculated, corrected for age and gender (F) Integrative 808 network of transcriptome, proteome and metabolome data. Nodes in the network correspond 809 to molecules (proteome, metabolome) or BTMs (transcriptome). Only molecules and 810 pathways identified by MOFA weights (Supplementary Figure 6F) are plotted. Edges in the 811 network (all adj. p-value < 0.05) are statistical associations from linear mixed models (see

812 Methods), where red edges represent positive associations and blue edges represent 813 negative associations.

814

815 Figure 5 Pre-vaccination plasma proteome correlates to the antibody response to 816 vaccination (A) Proportion of co-variation in proteome and antibody fold change explained by 817 each component for either each strain or the predictors examined through PLSR analysis 818 with 10-fold cross validations (N = 200). The first three components using the predictors 819 were able to explain ~ 40% co-variation in the antibody response and pre-vaccination protein 820 abundance (B) Heatmap of t-test statistics for top predictors with antibody fold change for 821 top three components as calculated using rank product analysis for these components. Most 822 proteins show heterogenous associations with the antibody fold change against the three 823 influenza strains, with notable exceptions for IL-15 and TNFSF13 in component 1. (C) 824 Correlation plots of IL-15 against antibody fold change for all 200 donors. (D)  $IL15RA^{+/+}$  and 825 IL15RA<sup>-/-</sup> mice were immunised with OVA-Alum or OVA-IFA in the footpad, followed by 826 analysis of antibody titres, and lymphocyte populations from inguinal lymph nodes 11 days 827 post-immunization. (E) Proportion of B (CD19+), T (CD3+), NK (NK1.1+) cells, as well as 828 CD4+ and CD8+ T cell subsets, among splenocytes of unimmunized IL15RA<sup>+/+</sup> and IL15RA<sup>-/-</sup> 829 mice. (F) Ratio of Tfh/Tfr cells, calculated from their frequency among total CD4+ cells, 830 within LNs of immunized IL15RA<sup>+/+</sup> and IL15RA<sup>-/-</sup> mice. (G) Serum concentration of OVA-831 specific IgG1 in mice immunized with OVA-alum, or (H) immunized with OVA-IFA. (I) 832 Schematic summarising the mechanism of IL-15-mediated activation of NK cells leading to 833 suppression of germinal centre responses and low production of antibodies.

834

835 Figure 6 Pre-vaccination plasma metabolites as modulators for vaccination response (A) 836 Proportion of co-variation in endogenous metabolites and antibody fold change explained by 837 each component for either each strain or the predictors examined through PLSR analysis 838 with 10-fold cross validations (N = 200). The first 8 components were able to explain  $\sim$  40% 839 co-variation in the antibody response and pre-vaccination metabolite abundance (B) Plot of 840 metabolites from component 1 with their ranks and estimated percentage of false predictions 841 (PFP) (left), Heatmap of t-test statistic for the top predictors with antibody fold change for the 842 top component as calculated using rank product analysis for these components (right). Most 843 metabolites show heterogeneous associations to the different influenza strains in the 844 vaccine, except for malic acid and citric acid showing negative association while betaine 845 shows positive association. (C) Correlation plots of malic acid against antibody fold change 846 for all three influenza strains for all 200 donors. (D) Association of malic acid to cytokine 847 production upon influenza stimulation in an independent cohort of 500 younger healthy 848 individuals, showing a negative trend. P-values are generated using t-test. Partial correlation 849 estimate was calculated, corrected for age and gender (E) Top metabolites for component 2 850 with their ranks and estimated percentage of false predictions shows long chain fatty acids 851 as top candidates. (F) Negative association of these long chain fatty acids identified in PLSR 852 component 2 with IL-15. P-values are generated using t-test. Partial correlation estimate was 853 calculated, corrected for age and gender (G) Schematic describing the role of IL-15 in 854 delayed neutrophil apoptosis, maturation and activation of NK cell populations, leading to 855 suppression of GC responses and reduced antibody production and a chronic inflammatory 856 status. Evidence for each observation is derived through different omics layers and 857 experiments. Connections among different observations were also supported by published 858 findings. 859

860

# 880 METHODS

882 Study population

The study population has been described before in detail by Riese, Akmatov and 883 884 colleagues<sup>7,17</sup>. Briefly, a prospective population-based study across two Influenza seasons 885 (2014/2015 and 2015/2016) was performed among elderly individuals (>65 years of age) 886 from Hannover, Germany. Donors from both seasons did not overlap. Participants were 887 recruited from a random sample from the local population registry and represented the general population as verified by a survey<sup>18</sup>. Intravenous blood samples were drawn before 888 889 vaccination (day 0) and on day 1, day 3, day 6/7, day 21 & day 70 post-vaccination. 890 Hemagglutination inhibition titres and microneutralization titres were measured as described 891 before'. Briefly, we followed the formulation of the Fluad vaccine and used the following 892 antigens for titre measurements in serum: H1N1 A/California/7/09 NYMC-X181 (both 893 seasons). H3N2 A/Texas/50/2012 NYMC-223 (season 2014/2015). H3N2 894 A/Switzerland/9715293/2013 NIB88 (season 2015/2016), B/Massachusetts/02/2012 NYMC 895 BX-51B (season 2014/2015) and B\Brisbane/9/2014 (season 2015/2016). Sero-conversion 896 was defined as either a post-vaccination titre of  $\geq$  40 for individuals with pre-vaccination titres 897 < 10, or a 4-fold increase in titre upon vaccination for individuals with pre-vaccination titre 898 ≥10. Individuals were classified as Triple Responders (TR, sero-conversion against all three 899 strains), Non-Responders (NR, no sero-conversion against any strain), or Other (sero-900 conversion against at least one strain but not all three).

901

#### 902 Bulk transcriptome sequencing

903 Bulk transcriptome sequencing has been described before<sup>7</sup>. In short, ten TRs and ten NRs 904 were selected based on their serological response to vaccination. We included five time 905 points per individual: baseline, day 1/3, day 6/7, day 21/35 & day 60/70. miRNA and total 906 RNA were purified from whole blood samples frozen in PAXgene<sup>™</sup> tubes (BD) using the 907 "PAXgene Blood miRNA Kit" (Qiagen). The detailed procedure was previously described<sup>7</sup>.

#### 908

#### 909 Untargeted metabolomics

910 We assessed the metabolic profiles of 702 individuals from two influenza seasons. Plasma 911 samples were randomised across plates with respect to vaccine response, sampling time 912 point and sex. Polar metabolites were extracted from each sample with 180 uL 80% 913 methanol in a deep well extraction plate using 20 uL plasma by General Metabolics, Boston, 914 USA. Samples were vortexed for 15 seconds, incubated at 4°C for one hour and centrifuged 915 at 4°C, 3750 RPM for 30 minutes. Metabolome profiles of the sample extracts were acquired 916 using flow-injection mass spectrometry. The method described here is adapted from previously described methods<sup>76</sup>. The instrumentation consisted of an Agilent 6550 iFunnel 917 918 LC-MS Q-TOF mass spectrometer in tandem with an MPS3 autosampler (Gerstel) and an 919 Agilent 1260 Infinity II quaternary pump. The running buffer was 60% isopropanol in water 920 (v/v) buffered with 1 mM ammonium fluoride. Hexakis (1H, 1H, 3H-tetrafluoropropoxy)-921 phosphazene) (Agilent) and 3-amino-1-propanesulfonic acid (HOT) (Sigma Aldrich). The 922 isocratic flow rate was set to 0.150 mL/min. The instrument was run in 4GHz High 923 Resolution, negative ionization mode. Mass spectra between 50 and 1,000 m/z were 924 collected in profile mode. 5 uL of each sample were injected twice, consecutively, within 0.96 925 minutes to serve as technical replicates. The pooled study sample was injected periodically 926 throughout the batch. Samples were acquired randomly within plates.

927

#### 928 Targeted metabolomics

929 Serum concentrations of amino acids were determined by mass spectrometry, using an 930 HPLC-coupled triple quadrupole mass spectrometer (AP4000, Siex) and the AbsoluteIDQ 931 p180 kit (Biocrates Life Science AG, Innsbruck, Austria) following the manufacturer's 932 protocols<sup>77</sup>.

933

### 934 Targeted proteomics

935 We measured 384 circulating proteins in plasma using Olink's proximity extension assay (PEA) Explore Inflammation panel<sup>78</sup> in 702 individuals. In the PEA, oligonucleotide-labelled 936 antibodies ('probes") bind the protein of interest. Linking of the probes is triggered by close 937 938 proximity of two antibodies which limits cross-reactivity. Upon linking, the probe sequence is 939 hybridised and subject to extension by DNA polymerases. The resulting sequence is 940 quantified by real-time polymerase chain reaction. Protein values are expressed as 941 normalised protein expression (NPX) values, a relative value on a log2 scale. Quality control 942 of the raw data was performed by Olink (incubation controls, extension controls and 943 detection controls).

944

## 945 Immunisation, cell isolation and blood serum collection of IL15RA<sup>-/-</sup> and IL15RA<sup>+/+</sup>mice

946 Sex-matched IL15RA<sup>-/-</sup> and IL15RA<sup>+/+</sup> C57BL/6 mice, aged from 10 to 12 weeks, were 947 immunized in the back paw footpad with Ovalbumin (OVA, Ovalbumin EndoFit, Invivogen, 948 #vac-pova) emulsified 1:1 (v:v) with either IFA (IFA, Sigma-Aldrich, #F5506) or Alum (Alu-949 Gel-S, Serva, #12261-01). Each animal was inoculated with a volume of 50 µl per paw 950 containing 80 µg of OVA (OVA-IFA was injected in two paws while OVA-Alum was injected 951 in one paw per mouse). Mice were sacrificed 11 days after immunisation and the cells from 952 the spleen and inguinal lymph nodes (LNs) isolated. Blood serum from each mouse was also 953 collected at the same time point by cardiac puncture. The mice were bred and maintained 954 under specific pathogen-free conditions at the Instituto de Medicina Molecular (iMM), where 955 the experiments were performed under an animal experimentation authorization granted by

Direção-Geral de Alimentação e Veterinária (DGAV), the Portuguese national authority for
animal health, and iMM-ORBEA, the Ethic Committee for laboratory animal care at the iMM
Rodent Facility in Lisbon.

## 959 *Flow cytometry of IL15RA<sup>-/-</sup>* and *IL15RA*<sup>+/+</sup>mice

Characterization of the lymphoid cell populations in the spleen of IL15RA<sup>-/-</sup> and IL15RA<sup>+/+</sup> 960 C57BL/6 strains was done by flow cytometry with the following antibodies: anti-CD19-FITC 961 962 (MB19-1, eBioscience; 1:100), anti-CD3-APC (145-2C11, eBioscience; 1:100), anti-CD4-963 BV510 (RM4-5, BioLegend; 1:400), anti-CD8-eF780 (53-6.7, eBioscience; 1:200), and anti-964 NK1.1-PECy7 (PK136, eBioscience; 1:100). B and T cells subpopulations present in the 965 inguinal LNs were first pre-incubated with anti-CXCR5-Biotin (2G8, BD Biosciences; 1:50) 966 and subsequently stained with anti-CD19-FITC (MB19-1, eBioscience; 1:100), anti-CD95-PE 967 (Jo2, BD Biosciences; 1:100), anti-ICOS-PerCPCy5.5 (7E.17G9, BioLegend; 1:200), anti-968 PD-1-PECy7 (J43, eBioscience; 1:100), anti-GL7-eF660 (GL-7, eBioscience; 1:100), anti-969 CD25-APCeF780 (PC61.5, eBioscience; 1:200), anti-CD4-BV510 (RM4-5, BioLegend; 970 1:400), and anti-CD44-BV605 (IM7, BioLegend; 1:400) together with Streptavidin-BV711 (BioLegend; 1:100). Intracellular Foxp3 (FJK-16s, eBioscience; 1:100) staining was 971 972 performed using the Foxp3 Fix/Perm Kit (eBioscience, #00-5521-00) according to the 973 manufacturer's instructions. The samples were acquired on a BD LSRFortessa cytometer 974 from the iMM Flow Cytometry Facility and further analyzed on FlowJo software (TreeStar).

975

## 976 Anti-OVA IgG quantification of IL15RA<sup>-/-</sup> and IL15RA<sup>+/+</sup>mice

977 Serum anti-OVA mouse IgG1 was quantified by ELISA. 96-well plate wells were coated with 978 50 μl OVA (Ovalbumin EndoFit, Invivogen, #vac-pova) at 20 μg/ml in PBS overnight (4 °C), 979 washed 3 times with ELISA Buffer (Invitrogen, #88-50620-88) and subsequently blocked 980 with 200 µl of ELISA Buffer for at least 30 minutes. After washing, standards and different 981 dilutions of each serum sample were plated in duplicates in the coated wells for at least 90 982 minutes. The standard curve was obtained with measurements from known concentrations 983 of Anti-OVA [6C8] IgG1 antibody (AbCam, #ab17293). After washing, 50 µl of anti-mouse-984 IgG1-HRP (SouthernBiotech, #1070-05) diluted 1:2000 were added to the wells and 985 incubated for at least 45 minutes. Wells were washed, and 50 µL of the substrate solution 986 3,3',5,5'-tetramethylbenzidine (TMB Single Solution, Life Technologies) were added per well. 987 The reaction was stopped with 25  $\mu$ L of sulfuric acid (H<sub>2</sub>SO<sub>4</sub>) according to the colour 988 development of the standards. Lastly, optical density (OD) was read at 450 nm within 30 989 seconds after stopping the reaction. Quantification of Anti-OVA mouse IgG1 in each sample 990 of blood serum was attained by calculating the concentration of antibody considering the OD 991 values obtained for a dilution that fitted within the OD values of the standard curve (0.2 > OD 992 < 1).

993

#### 994 Flow cytometry of human PBMCs

995 Cryopreserved PBMCs were thawed, rested for 2 h and incubated overnight with purified
996 anti-human CD28 and CD49d at a concentration of 10 µg/ml. For surface staining, cells were
997 incubated with the antibody mixture prepared in PBS for 30 min at 4°C in the dark. Cells
998 were stained for flow cytometric analysis using the following antibodies: CD3 (BUV395, SK7,
999 Cat.-No. 564001, dilution 1:200, BD (Franklin Lakes, New Jersey, USA)) and CD56 (BV785,
5.1H11, Cat.-No. 362550, dilution 1:100, BioLegend (San Diego, USA)). The samples were

acquired at a BD Fortessa flow cytometer using the Diva software and analyzed usingFlowJo.

1003

#### 1004 Statistical analyses

#### 1005 Bulk transcriptome analysis

We quantified bulk RNA sequencing data using Salmon<sup>79</sup> using default parameters and the 1006 1007 human GRCh38 genome. To check for potential outliers, we performed principal component 1008 analysis (PCA). No samples were removed based on this analysis. We then imported the 1009 transcript-level quantifications and transcript lengths using tximport<sup>80</sup> and quantified the 1010 differential expression between responder groups and over time points using a limma-voom 1011 approach<sup>81,82</sup>: gene ~ responder + age + Time +sex + 1|donor. For time dynamics, following 1012 linear model was used: gene ~ responderTime + age + sex + 1|donor. Functional enrichment 1013 was performed using gene set enrichment analysis (GSEA) using blood transcription modules (BTMs)<sup>23</sup>. Genes were ranked by t-test statistic from this mixed linear model for the 1014 1015 comparison of interest. P-values were adjusted using Benjamini-Hochberg, where we 1016 considered adj. p value < 0.01 significant or adj. p value < 0.05.

1017

1018 The relative contribution of individual cell types was estimated using CIBERSORT<sup>24</sup>. using 1019 the LMM22 background. We defined the pathway activity as the mean expression corrected 1020 for variance across donors of all genes assigned to a specific BTM per sample. A linear 1021 model was used to associate the estimated proportions of individual cell types to functional 1022 pathways: cell proportion ~ BTM\_score + age + sex + 1/donor, done separately for TRs and 1023 NRs. where BTM score is the BTM score as described above and cell proportion is the 1024 estimated cellular proportions from CIBERSORT per individual. P-values were adjusted on 1025 all associations using Benhamini-Hochberg. We considered adj. p-values < 0.05 to be 1026 significant.

1027

#### 1028 *Targeted proteomics*

We removed measurements that were flagged as unreliable by Olink as well as protein assays where the target protein was detected in less than 70% of the samples. Finally, we considered 311 high-quality proteome assays for further downstream analyses. We performed dimensionality reduction (PCA) to check for potential outliers or batch effects and did not identify either.

1034

1035 To quantify the differences in protein abundances between timepoints within each responder 1036 group separately, we fit a linear mixed model using limma<sup>81</sup>: *protein* ~ *time\_responder* + age 1037 + *sex* + 1/*donor*, where *time\_responder* indicates the sampling time point and responder 1038 group, and *donor* is the random effect. Benjamini-Hochberg post-hoc correction was used to 1039 control the false discovery rate across all proteins. We considered adjusted p-values < 0.05 1040 significant.

1041

#### 1042 Untargeted metabolomics

1043 Raw metabolite profile data were centroided, merged and recalibrated using MATLAB 1044 software as previously described<sup>76</sup>. Putative annotations were generated based on 1045 compounds contained in the HMDB<sup>83</sup> database using both accurate mass per charge and 1046 isotopic correlation patterns. We retained only ions that were confidently annotated, allowing 1047 0.001 Da tolerance between the ion and its corresponding annotation. Since exogenous

1048 and/or drug-related metabolites do not reflect an individual's current immune status and 1049 could lead to possibly confounding effects, we aimed to consider a set of endogenous 1050 metabolites. To do so, considered endogenous metabolites from HMDB and matched this to 1051 our annotated metabolite data based on the ion's chemical formula. Then, we manually re-1052 checked whether metabolites were drug-related using the DrugBank database<sup>84</sup>. Metabolites 1053 associated with medications or other xenobiotics were removed. Finally, we retained 192 1054 endogenous metabolites for further analyses.

1055

1056 We validated the quality of our untargeted metabolome data by using a targeted 1057 metabolomic approach on a subset of the individuals. We manually correlated 18 primary 1058 amino acids that were reliably detected and annotated between the two platforms and 1059 observed good replicability (median Pearson's r = 0.77). This indicates good sample quality 1060 and reliable, consistent measurements (Supplementary Figure 11).

1061

We fit a linear mixed model in limma<sup>81</sup> to quantify differences in endogenous metabolic 1062 1063 abundances within responder groups over time: metabolite ~ time responder + age + sex + 1064 1/donor, where time responder indicates the sampling time point and responder group, and 1065 donor is the random effect. We applied Benjamini-Hochberg post-hoc correction on all 1066 endogenous metabolites and considered metabolites with adjusted p-values < 0.051067 significant. Metabolite classifications to annotate metabolites were retrieved from HMDB. We 1068 performed metabolite enrichment by performing over-representation analysis using IMPALA<sup>85</sup>. Adjusted p-values (Benjamini-Hochberg) < 0.05 were considered significant. 1069

1070

#### 1071 Integration of transcriptome, proteome and metabolome layers

1072 We aimed to provide a comprehensive integration of the different data layers that were 1073 generated. To do so, we employed two approaches. First, we associated circulating protein 1074 and metabolite levels to transcriptome pathway activity. We defined pathway activity as 1075 described above. Proteins and metabolites were selected when differentially abundant at 1076 Day 7 compared to Day 0. Associations were estimated using a linear mixed model: protein 1077  $\sim$  age + gender + BTM + 1/donor. P-values were adjusted using Benhamini-Hochberg over 1078 all obtained associations, and adjusted p-values < 0.05 were considered significant. We 1079 performed this analysis for Day 7 as we observe the peak of the adaptive immune response 1080 to vaccination on this day.

1081

Next, we used Multi-Omics Factor Analysis (MOFA)<sup>37</sup> to perform unsupervised integration of 1082 1083 all layers. We chose day 0, day 7 and day 35 as we had datasets for these time points 1084 across all layers for the highest (N = 10) and lowest (N = 10) responders. For transcriptome, 1085 the top highly variable genes were selected. For proteome and metabolome, we removed 1086 molecules that were significantly (nominal p-value < 0.05) associated with sex. Finally, we 1087 considered 1560 genes, 279 proteins and 158 metabolites across three timepoints for further 1088 analysis using MOFA. We applied MOFA standard practices and trained the model on a 1089 single group. The default data and training model options were used except for scale views set to TRUE. Following model training, MOFA reported factor 1 correlated with technical 1090 1091 variation and we thus did not consider this factor. The rest of the factors were evaluated for 1092 significance with either Responder Category, Age, Gender and Time by testing the factor 1093 values using a Wilcoxon ranked-sum test. For the factors that are shown, weights are scaled 1094 for each layer independently and used to identify the top predictors for proteome and 1095 metabolome. For network building, we performed GSEA using BTMs on the transcripts

1096 ranked by MOFA's scaled weights, and considered adjusted p-values < 0.05 significant. For 1097 proteome and metabolome, molecules with absolute scaled weights > 0.25 for factor 3 were 1098 considered and their associations done, similar to BTMs. Associations across layers of 1099 protein and metabolite molecules to different BTMs controlling for repeated measurements 1100 from the same donors were done and associations with adjusted p-values < 0.05 were 1101 selected. Across-layers associations were also calculated and significant associations were kept. Cytoscape<sup>86</sup> was used to build the multi-laver network with colour of the nodes 1102 1103 representing factor 3 scaled weights for each protein or metabolite, or enrichment score for 1104 transcriptome BTMs.

1105

#### 1106 Partial least-squares regression

1107 We employed partial least-squares regression (PLSR) to identify the pre-vaccination proteins 1108 and metabolites that are most consistently associated with the serological response against 1109 the three influenza strains. PLSR was performed using the pls library in R for proteome and 1110 metabolome separately using all 200 donors of the discovery cohort. The model was run for 1111 100 independent iterations with 10-fold cross-validations (e.g. 90% training, 10% testing) 1112 and we calculated the proportion of variation explained by each PLSR component. For the 1113 first 3 components we performed rank-product analysis over the 100 iterations to identify the 1114 top predictors. The top 30 ranked molecules (either proteins or metabolites) were then 1115 evaluated for their positive or negative association with antibody fold change.

- 1116
- 1117
- 1118
- 1119 1120
- 1121
- 1122
- 1123

1125

#### 1124 SUPPLEMENTAL INFORMATION TITLES AND LEGEND

1126 Supplementary Figure 1 General demographic factors associated to the serological 1127 response to trivalent inactivated influenza vaccination. (A) Correlation among 1128 hemagglutination (HAI) titers fold-change upon vaccination. In both seasons, HAI titers 1129 against each of the three strains are moderately positively correlated to each other. (B) 1130 Correlation between MN titers and HAI titers across two influenza seasons. Each dot is a 1131 sample, colours represent influenza strains. (C) Impact of sex on the serological response to 1132 TIV across two seasons. P-values were generated using the Wilcoxon ranked-sum test. (D) 1133 Influence of age on the HAI and microneutralization (MN) titers. Each dot is an individual, 1134 colours represent the different influenza strains.

1135

Supplementary Figure 2 Differences in cellular populations between responders and nonresponders. (A) Deconvoluted cellular populations were estimated using CIBERSORT from bulk transcriptomics data (n=10 TR, n=10 NR) across five different timepoints. Each point indicates a sample (NR=blue, TR-red). The curve is a smooth fitted line with standard error of the estimation. (B) CBC at T1 (pre-vaccination) for Neutrophils, Leucocytes and Monocytes for 200 donors. Samples are stratified by their responder status: TR, Other or NR.

Supplementary Figure 3 *Time dynamics and BTMs in TRs and NRs.* (A) Significant BTMs upregulated in TRs and NRs at pre-vaccination stage. (B) Genes enriched for inflammatory BTMs and their expression in TRs and NRs. Only CD83 and IL23A are significantly (adjusted p-value < 0.05) upregulated in TRs (C) Number of significantly differentially expressed genes in TRs and NRs, 3days, 7 days, 35 days and 70 days post vaccination. (E) Top 20 significantly upregulated in TRs (left), NRs (right) 7 days post vaccination.

1151

Supplementary Figure 4 NK cell flow cytometry results from the replication cohort. Total NK
cell proportions (top), CD56dim (middle) and CD56bright (bottom) flow cytometry results
from NRs (n=2, except day 6/7 where n=1) and TRs (n=5).

1155

1156 Supplementary Figure 5 Proteomic and metabolomic response to TIV. (A) CLECL7A proteome abundance in all TRs (red) and NRs (blue) over time in the Discovery cohort (top) 1157 1158 and the Replication cohort (bottom). (B) Proteome differential abundance results in the 1159 replication cohort. (C) Volcano plots showing differential abundance results comparing Day 1160 35 vs Day 0 for TRs (left) and NRs (right) in discovery cohort. Red dots represent 1161 significantly different proteins at adjusted p-value < 0.05. (D) Annotation of the differentially 1162 abundant metabolites found in the replication cohort. Baseline represents the universe of all 1163 metabolites measured, whereas TR and NR show significantly differentially abundant 1164 metabolites (nominal p < 0.05) at T3 and T4, respectively. (E) Subclass annotation of 1165 upregulated organic acids (top) and lipids and lipid-like molecules (bottom). These 1166 metabolites were significantly differentially abundant (adjusted p < 0.05) in the discovery 1167 cohort. Pie charts indicate the distribution of significant metabolites within the fatty acids and 1168 conjugates classification. (F) Alluvial plot showing the differential expression results for TRs 1169 (left) and NRs (right) at the different timepoints compared to baseline in the discovery cohort 1170 (n=81). Significant metabolites shown (adjusted p-value < 0.05).

1171

Supplementary Figure 6 Proteins upregulated in NRs 7 days post vaccination and their
 correlation with transcriptome chronic inflammatory BTMs. Most proteins show a negative
 correlation with unadjusted p-value < 0.05.</li>

1175

1176 Supplementary Figure 7 Multiomics integration capturing different dynamics in TRs and 1177 NRs. (A) Factor 4 and Factor 6 showing time variation captured in TRs. Factor 4 is 1178 exclusively explained by transcriptome while factor 6 is explained by both transcriptome and 1179 proteome. (B) Abundance of top factor 3 proteins and metabolites in all 81 TRs and NRs. (C) 1180 Methionine positive correlation with cytokine production post influenza stimulation in 500FG 1181 cohort. (D) Distribution of scaled weights attributed to proteins, metabolites and enrichment 1182 score for transcripts. Molecules with scaled weights of absolute value > = 0.25 were 1183 considered for network generation in Figure 4E.

1184

Supplementary Figure 8 *Pre-vaccination correlates* (A) Plot of TNFSF13/APRIL against
log2 antibody fold change of each strain in discovery (left) and replication cohort (right). (B)
Plot of IL15 against antibody fold change of each strain in replication cohort. (C) Expression
of IL-15 in human PBMCs using single-cell RNA sequencing data.

1189

1190 **Supplementary Figure 9** *IL15RA-/- mice experiments* **(A)** Representative flow cytometry 1191 plots showing the frequency of B cells (CD19+) and T cells (CD3+) in the spleen of IL15RA<sup>-/-</sup>

mice (left plot), and the NK cell frequency (NK1.1+) among splenocytes from IL15RA<sup>+/+</sup> and IL15RA<sup>-/-</sup> mice (two plots on the right). (B) The dot plots represent the frequency of total B cells, GC B cells, total CD4+T cells, CD4+Foxp3- Tconv cells, CD4+Foxp3+ Treg cells, Tfh, and Tfr cells in inguinal lymph nodes from IL15RA+/+ and IL15RA-/- mice. Pooled data from two independent experiments; n=8 to 10.

1197

1198 Supplementary Figure 10 Pre-vaccination metabolite correlates with antibody fold change. 1199 (A) Plot of citric acid against antibody fold change for each strain. (B) Plot of citric acid 1200 abundance against cell proportions calculated from 300BCG cohort. (C) Plot of betaine(top) 1201 and cysteine(bottom) abundance against antibody fold change for each strain. (D) Additional 1202 unsaturated long chain fatty acids negatively correlated to IL15. (E) Estimate of protein (42) 1203 associations to all fatty acids for ~200 elderly donors (left) and to ~ 500 young donors (right). 1204 In the elderly, LCFA negatively correlated to most proteins while other fatty acids (FAs) show 1205 both positive and negative correlation while no such pattern observed in the younger cohort. 1206 Associations with p-value <0.05 plotted.

1207

Supplementary Figure 11 Replicability of untargeted metabolomic profiles. We manually correlated 19 primary amino acids that were confidently detected in both the untargeted and targeted metabolomics dataset. Each dot indicates a sample, coloured for time (10TRs, 10NRs across three timepoints). We observe good replicability for the primary amino acids.

- 1212
- 1213
- 1214
- 1215
- 1216
- 1217
- 1218
- 1219
- 1220

REFERENCES

- 1221
  1. Iuliano, A.D., Roguski, K.M., Chang, H.H., Muscatello, D.J., Palekar, R., Tempia, S., Cohen, C., Gran, J.M., Schanzer, D., Cowling, B.J., et al. (2018). Estimates of global seasonal influenza-associated respiratory mortality: a modelling study.
  1224 The Lancet 391, 1285–1300. 10.1016/S0140-6736(17)33293-2.
- 1225 2. Osterholm, M.T., Kelley, N.S., Sommer, A., and Belongia, E.A. (2012). Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. The Lancet Infectious Diseases *12*, 36–44. 10.1016/S1473-3099(11)70295-X.
- 1227
   3. Ferdinands, J.M., Thompson, M.G., Blanton, L., Spencer, S., Grant, L., and Fry, A.M. (2021). Does influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further research. Vaccine 39, 3678–3695. 10.1016/j.vaccine.2021.05.011.
- 1230 4. Lang, P.-O., Mendes, Socquet, Assir, Govind, and Aspinall (2012). Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence. CIA, 55. 10.2147/CIA.S25215.
- 1232 5. Jefferson, T., Rivetti, D., Rivetti, A., Rudin, M., Di Pietrantonj, C., and Demicheli, V. (2005). Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. The Lancet 366, 1165–1174. 10.1016/S0140-6736(05)67339-4.
- 1234 6. Goronzy, J.J., and Weyand, C.M. (2013). Understanding immunosenescence to improve responses to vaccines. Nat Immunol *14*, 428–436. 10.1038/ni.2588.
- Riese, P., Trittel, S., Akmatov, M.K., May, M., Prokein, J., Illig, T., Schindler, C., Sawitzki, B., Elfaki, Y., Floess, S., et al. (2022). Distinct immunological and molecular signatures underpinning influenza vaccine responsiveness in the elderly. Nat Commun *13*, 6894. 10.1038/s41467-022-34487-z.

- Nakaya, H.I., Hagan, T., Duraisingham, S.S., Lee, E.K., Kwissa, M., Rouphael, N., Frasca, D., Gersten, M., Mehta, A.K., Gaujoux, R., et al. (2015). Systems Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse Populations Reveals Shared Molecular Signatures. Immunity 43, 1186–1198. 10.1016/j.immuni.2015.11.012.
- Nipper, A.J., Smithey, M.J., Shah, R.C., Canaday, D.H., and Landay, A.L. (2018). Diminished antibody response to influenza vaccination is characterized by expansion of an age-associated B-cell population with low PAX5. Clinical Immunology *193*, 80–87. 10.1016/j.clim.2018.02.003.
- 1245 10. Frasca, D., Diaz, A., Romero, M., Garcia, D., and Blomberg, B.B. (2020). B Cell Immunosenescence. Annu. Rev. Cell Dev. Biol. *36*, 551–574. 10.1146/annurev-cellbio-011620-034148.
- Wimmers, F., Donato, M., Kuo, A., Ashuach, T., Gupta, S., Li, C., Dvorak, M., Foecke, M.H., Chang, S.E., Hagan, T., et al. (2021). The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination. Cell *184*, 3915-3935.e21. 10.1016/j.cell.2021.05.039.
- Hagan, T., Cortese, M., Rouphael, N., Boudreau, C., Linde, C., Maddur, M.S., Das, J., Wang, H., Guthmiller, J., Zheng, N.-Y., et al. (2019). Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans. Cell *178*, 1313-1328.e13. 10.1016/j.cell.2019.08.010.
- 1253 13. Fourati, S., Tomalin, L.E., Mulè, M.P., Chawla, D.G., Gerritsen, B., Rychkov, D., Henrich, E., Miller, H.E.R., Hagan, T., Diray-Arce, J., et al. (2022). Pan-vaccine analysis reveals innate immune endotypes predictive of antibody responses to vaccination. Nat Immunol 23, 1777–1787. 10.1038/s41590-022-01329-5.
- 1256 14. Kelly, B., and Pearce, E.L. (2020). Amino Assets: How Amino Acids Support Immunity. Cell Metabolism 32, 154–175. 10.1016/j.cmet.2020.06.010.
- 1258
   15. Ganeshan, K., and Chawla, A. (2014). Metabolic Regulation of Immune Responses. Annu. Rev. Immunol. 32, 609–634.

   10.1146/annurev-immunol-032713-120236.
- 1260
   16. Chou, C., Mohanty, S., Kang, H.A., Kong, L., Avila-Pacheco, J., Joshi, S.R., Ueda, I., Devine, L., Raddassi, K., Pierce, K., et al. (2022). Metabolomic and transcriptomic signatures of influenza vaccine response in healthy young and older adults. Aging Cell *21*. 10.1111/acel.13682.
- 1263
  17. Akmatov, M.K., Riese, P., May, M., Jentsch, L., Ahmed, M.W., Werner, D., Rösel, A., Tyler, M., Pessler, K., Prokein, J., et al. (2017). Establishment of a cohort for deep phenotyping of the immune response to influenza vaccination among elderly individuals recruited from the general population. Human Vaccines & Immunotherapeutics *13*, 1630–1639.
  10.1080/21645515.2017.1299300.
- 1267
  18. Akmatov, M.K., Jentsch, L., Riese, P., May, M., Ahmed, M.W., Werner, D., Rösel, A., Prokein, J., Bernemann, I., Klopp, N., et al. (2017). Motivations for (non)participation in population-based health studies among the elderly – comparison of participants and nonparticipants of a prospective study on influenza vaccination. BMC Med Res Methodol *17*, 18. 10.1186/s12874-017-0302-z.
- 1271
   19. Akmatov, M.K., Riese, P., Trittel, S., May, M., Prokein, J., Illig, T., Schindler, C., Guzmán, C.A., and Pessler, F. (2019).
   Self-reported diabetes and herpes zoster are associated with a weak humoral response to the seasonal influenza A H1N1 vaccine antigen among the elderly. BMC Infect Dis *19*, 656. 10.1186/s12879-019-4214-x.
- Nakaya, H.I., Wrammert, J., Lee, E.K., Racioppi, L., Marie-Kunze, S., Haining, W.N., Means, A.R., Kasturi, S.P., Khan, N., Li, G.-M., et al. (2011). Systems biology of vaccination for seasonal influenza in humans. Nat Immunol *12*, 786–795.
   10.1038/ni.2067.
- 1277
   21. Avey, S., Mohanty, S., Chawla, D.G., Meng, H., Bandaranayake, T., Ueda, I., Zapata, H.J., Park, K., Blevins, T.P., Tsang, S., et al. (2020). Seasonal Variability and Shared Molecular Signatures of Inactivated Influenza Vaccination in Young and Older Adults. The Journal of Immunology 204, 1661–1673. 10.4049/jimmunol.1900922.
- 1280
  22. Olafsdottir, T.A., Alexandersson, K.F., Sveinbjornsson, G., Lapini, G., Palladino, L., Montomoli, E., Del Giudice, G., Gudbjartsson, D.F., and Jonsdottir, I. (2018). Age and Influenza-Specific Pre-Vaccination Antibodies Strongly Affect Influenza Vaccine Responses in the Icelandic Population whereas Disease and Medication Have Small Effects. Front. Immunol. *8*, 1872. 10.3389/fimmu.2017.01872.
- 1284<br/>1285<br/>128623. Li, S., Rouphael, N., Duraisingham, S., Romero-Steiner, S., Presnell, S., Davis, C., Schmidt, D.S., Johnson, S.E., Milton,<br/>A., Rajam, G., et al. (2014). Molecular signatures of antibody responses derived from a systems biology study of five<br/>human vaccines. Nat Immunol 15, 195–204. 10.1038/ni.2789.
- Newman, A.M., Liu, C.L., Green, M.R., Gentles, A.J., Feng, W., Xu, Y., Hoang, C.D., Diehn, M., and Alizadeh, A.A. (2015). Robust enumeration of cell subsets from tissue expression profiles. Nat Methods *12*, 453–457. 10.1038/nmeth.3337.
- 1290 1291 25. Wang, Y., Wang, X., Jia, X., Li, J., Fu, J., Huang, X., Cui, X., Wang, B., Luo, W., Lin, C., et al. (2023). Influenza vaccination features revealed by a single-cell transcriptome atlas. Journal of Medical Virology *95*. 10.1002/jmv.28174.

- 1292 26. Koutsakos, M., Wheatley, A.K., Loh, L., Clemens, E.B., Sant, S., Nüssing, S., Fox, A., Chung, A.W., Laurie, K.L., Hurt, A.C., et al. (2018). Circulating T <sub>FH</sub> cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity. Sci. Transl. Med. *10*, eaan8405. 10.1126/scitranslmed.aan8405.
- 1295 27. Castigli, E., Wilson, S.A., Scott, S., Dedeoglu, F., Xu, S., Lam, K.-P., Bram, R.J., Jabara, H., and Geha, R.S. (2005). TACI and BAFF-R mediate isotype switching in B cells. Journal of Experimental Medicine 201, 35–39. 10.1084/jem.20032000.
- 1297
   28. Mantchev, G.T., Cortesão, C.S., Rebrovich, M., Cascalho, M., and Bram, R.J. (2007). TACI Is Required for Efficient Plasma Cell Differentiation in Response to T-Independent Type 2 Antigens. The Journal of Immunology 179, 2282–2288. 10.4049/jimmunol.179.4.2282.
- 1300
   29. de Groen, R.A., Groothuismink, Z.M.A., Liu, B.-S., and Boonstra, A. (2015). IFN-λ is able to augment TLR-mediated activation and subsequent function of primary human B cells. Journal of Leukocyte Biology *98*, 623–630.
   10.1189/jlb.3A0215-041RR.
- Hemann, E.A., Green, R., Turnbull, J.B., Langlois, R.A., Savan, R., and Gale, M. (2019). Interferon-λ modulates dendritic cells to facilitate T cell immunity during infection with influenza A virus. Nat Immunol 20, 1035–1045. 10.1038/s41590-019-0408-z.
- Schaller, T.H., Batich, K.A., Suryadevara, C.M., Desai, R., and Sampson, J.H. (2017). Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3. Expert Review of Clinical Immunology *13*, 1049–1060.
   10.1080/1744666X.2017.1384313.
- 1309 1310
   32.
   Pazzaglia, S., and Pioli, C. (2019). Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases. Cells 9, 41. 10.3390/cells9010041.
- 1311<br/>131233. Shou, Q., Fu, H., Huang, X., and Yang, Y. (2019). PARP-1 controls NK cell recruitment to the site of viral infection. JCI<br/>Insight 4, e121291. 10.1172/jci.insight.121291.
- 1313
  34. Wang, L., Niu, Z., Wang, X., Li, Z., Liu, Y., Luo, F., and Yan, X. (2020). PHD2 exerts anti-cancer and anti-inflammatory effects in colon cancer xenografts mice via attenuating NF-κB activity. Life Sciences 242, 117167. 10.1016/j.lfs.2019.117167.
- 1316 1317 35. Bao, J., Pan, G., Poncz, M., Wei, J., Ran, M., and Zhou, Z. (2018). Serpin functions in host-pathogen interactions. PeerJ 6, e4557. 10.7717/peerj.4557.
- 1318
  1319
  36. Battaglia, S., De Santis, S., Rutigliano, M., Sallustio, F., Picerno, A., Frassanito, M.A., Schaefer, I., Vacca, A., Moschetta, A., Seibel, P., et al. (2021). Uridine and pyruvate protect T cells' proliferative capacity from mitochondrial toxic antibiotics: a clinical pilot study. Sci Rep *11*, 12841. 10.1038/s41598-021-91559-8.
- Argelaguet, R., Velten, B., Arnol, D., Dietrich, S., Zenz, T., Marioni, J.C., Buettner, F., Huber, W., and Stegle, O. (2018).
   Multi-Omics Factor Analysis—a framework for unsupervised integration of multi-omics data sets. Mol Syst Biol *14*.
   10.15252/msb.20178124.
- 1324
  38. Bakker, O.B., Aguirre-Gamboa, R., Sanna, S., Oosting, M., Smeekens, S.P., Jaeger, M., Zorro, M., Võsa, U., Withoff, S., Netea-Maier, R.T., et al. (2018). Integration of multi-omics data and deep phenotyping enables prediction of cytokine responses. Nat Immunol *19*, 776–786. 10.1038/s41590-018-0121-3.
- Li, Y., Oosting, M., Smeekens, S.P., Jaeger, M., Aguirre-Gamboa, R., Le, K.T.T., Deelen, P., Ricaño-Ponce, I.,
   Schoffelen, T., Jansen, A.F.M., et al. (2016). A Functional Genomics Approach to Understand Variation in Cytokine
   Production in Humans. Cell *167*, 1099-1110.e14. 10.1016/j.cell.2016.10.017.
- 1330<br/>133140. Linden, J., Koch-Nolte, F., and Dahl, G. (2019). Purine Release, Metabolism, and Signaling in the Inflammatory<br/>Response. Annu. Rev. Immunol. 37, 325–347. 10.1146/annurev-immunol-051116-052406.
- 1332 41. Idzko, M., Ferrari, D., and Eltzschig, H.K. (2014). Nucleotide signalling during inflammation. Nature *509*, 310–317. 10.1038/nature13085.
- Nakamura, R., Maeda, N., Shibata, K., Yamada, H., Kase, T., and Yoshikai, Y. (2010). Interleukin-15 Is Critical in the Pathogenesis of Influenza A Virus-Induced Acute Lung Injury. J Virol 84, 5574–5582. 10.1128/JVI.02030-09.
- 1336
   43. Verbist, K.C., Rose, D.L., Cole, C.J., Field, M.B., and Klonowski, K.D. (2012). IL-15 Participates in the Respiratory Innate Immune Response to Influenza Virus Infection. PLoS ONE 7, e37539. 10.1371/journal.pone.0037539.
- Tran, A.T., Rahim, M.N., Ranadheera, C., Kroeker, A., Cortens, J.P., Opanubi, K.J., Wilkins, J.A., and Coombs, K.M. (2013). Knockdown of specific host factors protects against influenza virus-induced cell death. Cell Death Dis 4, e769–e769. 10.1038/cddis.2013.296.

- Debisarun, P.A., Gössling, K.L., Bulut, O., Kilic, G., Zoodsma, M., Liu, Z., Oldenburg, M., Rüchel, N., Zhang, B., Xu, C.-J., et al. (2021). Induction of trained immunity by influenza vaccination - impact on COVID-19. PLoS Pathog *17*, e1009928.
- 1344
  46. Carson, W.E., Giri, J.G., Lindemann, M.J., Linett, M.L., Ahdieh, M., Paxton, R., Anderson, D., Eisenmann, J., Grabstein, K., and Caligiuri, M.A. (1994). Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. Journal of Experimental Medicine *180*, 1395–1403. 10.1084/jem.180.4.1395.
- 1347
   47. Ma, S., Caligiuri, M.A., and Yu, J. (2022). Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy. Trends in Immunology 43, 833–847. 10.1016/j.it.2022.08.004.
- Huntington, N.D., Legrand, N., Alves, N.L., Jaron, B., Weijer, K., Plet, A., Corcuff, E., Mortier, E., Jacques, Y., Spits, H., et al. (2009). IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. Journal of Experimental Medicine 206, 25–34. 10.1084/jem.20082013.
- Rydyznski, C., Daniels, K.A., Karmele, E.P., Brooks, T.R., Mahl, S.E., Moran, M.T., Li, C., Sutiwisesak, R., Welsh, R.M., and Waggoner, S.N. (2015). Generation of cellular immune memory and B-cell immunity is impaired by natural killer cells. Nat Commun *6*, 6375. 10.1038/ncomms7375.
- 1355
   50. Rydyznski, C.E., Cranert, S.A., Zhou, J.Q., Xu, H., Kleinstein, S.H., Singh, H., and Waggoner, S.N. (2018). Affinity Maturation Is Impaired by Natural Killer Cell Suppression of Germinal Centers. Cell Reports 24, 3367-3373.e4.
   10.1016/j.celrep.2018.08.075.
- 1358
  1359
  51. Wollenberg, I., Agua-Doce, A., Hernández, A., Almeida, C., Oliveira, V.G., Faro, J., and Graca, L. (2011). Regulation of the Germinal Center Reaction by Foxp3+ Follicular Regulatory T Cells. The Journal of Immunology *187*, 4553–4560.
  10.4049/jimmunol.1101328.
- 1361<br/>136252. Stebegg, M., Kumar, S.D., Silva-Cayetano, A., Fonseca, V.R., Linterman, M.A., and Graca, L. (2018). Regulation of the<br/>Germinal Center Response. Front. Immunol. 9, 2469. 10.3389/fimmu.2018.02469.
- 1363
  1364
  53. Chu, X., Jaeger, M., Beumer, J., Bakker, O.B., Aguirre-Gamboa, R., Oosting, M., Smeekens, S.P., Moorlag, S., Mourits, V.P., Koeken, V.A.C.M., et al. (2021). Integration of metabolomics, genomics, and immune phenotypes reveals the causal roles of metabolites in disease. Genome Biol *22*, 198. 10.1186/s13059-021-02413-z.
- 1366
  54. Aguirre-Gamboa, R., Joosten, I., Urbano, P.C.M., van der Molen, R.G., van Rijssen, E., van Cranenbroek, B., Oosting, M., Smeekens, S., Jaeger, M., Zorro, M., et al. (2016). Differential Effects of Environmental and Genetic Factors on T and B Cell Immune Traits. Cell Reports *17*, 2474–2487. 10.1016/j.celrep.2016.10.053.
- 1369<br/>137055. Xia, Y., Chen, S., Zhu, G., Huang, R., Yin, Y., and Ren, W. (2018). Betaine Inhibits Interleukin-1β Production and<br/>Release: Potential Mechanisms. Front. Immunol. 9, 2670. 10.3389/fimmu.2018.02670.
- 1371 1372 56. Zhao, G., He, F., Wu, C., Li, P., Li, N., Deng, J., Zhu, G., Ren, W., and Peng, Y. (2018). Betaine in Inflammation: Mechanistic Aspects and Applications. Front. Immunol. *9*, 1070. 10.3389/fimmu.2018.01070.
- 1373<br/>1374<br/>137457. Go, E.K., Jung, K.J., Kim, J.Y., Yu, B.P., and Chung, H.Y. (2005). Betaine Suppresses Proinflammatory Signaling During<br/>Aging: The Involvement of Nuclear Factor- B via Nuclear Factor-Inducing Kinase/I B Kinase and Mitogen-Activated<br/>Protein Kinases. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 60, 1252–1264.<br/>10.1093/gerona/60.10.1252.
- 1377 58. Eggersdorfer, M., Berger, M.M., Calder, P.C., Gombart, A.F., Ho, E., Laviano, A., and Meydani, S.N. (2022). Perspective: Role of Micronutrients and Omega-3 Long-Chain Polyunsaturated Fatty Acids for Immune Outcomes of Relevance to Infections in Older Adults—A Narrative Review and Call for Action. Advances in Nutrition *13*, 1415–1430.
  10.1093/advances/nmac058.
- Venn-Watson, S.K., and Butterworth, C.N. (2022). Broader and safer clinically-relevant activities of pentadecanoic acid compared to omega-3: Evaluation of an emerging essential fatty acid across twelve primary human cell-based disease systems. PLoS ONE *17*, e0268778. 10.1371/journal.pone.0268778.
- 1384<br/>1385<br/>138660. Venn-Watson, S., Lumpkin, R., and Dennis, E.A. (2020). Efficacy of dietary odd-chain saturated fatty acid pentadecanoic<br/>acid parallels broad associated health benefits in humans: could it be essential? Sci Rep 10, 8161. 10.1038/s41598-020-<br/>64960-y.
- 1387
   61. Riese, P., Trittel, S., Pathirana, R.D., Klawonn, F., Cox, R.J., and Guzmán, C.A. (2020). Responsiveness to Influenza

   Vaccination Correlates with NKG2C-Expression on NK Cells. Vaccines 8, 281. 10.3390/vaccines8020281.
- 1389
   62.
   Pereira, B., Xu, X.-N., and Akbar, A.N. (2020). Targeting Inflammation and Immunosenescence to Improve Vaccine Responses in the Elderly. Front. Immunol. *11*, 583019. 10.3389/fimmu.2020.583019.

- Kathuria, N., Kraynyak, K.A., Carnathan, D., Betts, M., Weiner, D.B., and Kutzler, M.A. (2012). Generation of antigen-specific immunity following systemic immunization with DNA vaccine encoding CCL25 chemokine immunoadjuvant. Human Vaccines & Immunotherapeutics *8*, 1607–1619. 10.4161/hv.22574.
- Barbul, A., Sisto, D., Wasserkrug, L., and Efron, G. (1981). Arginine stimulates lymphocyte immune response in healthy human beings. Surgery *90*, 244–251.
- 1396<br/>139765. Moriguti, J.C., Ferriolli, E., Donadi, E.A., and Marchini, J.S. (2005). Effects of arginine supplementation on the humoral<br/>and innate immune response of older people. Eur J Clin Nutr 59, 1362–1366. 10.1038/sj.ejcn.1602247.
- 1398
   66.
   Wu, X., Sun, M., Yang, Z., Lu, C., Wang, Q., Wang, H., Deng, C., Liu, Y., and Yang, Y. (2021). The Roles of CCR9/CCL25 in Inflammation and Inflammation-Associated Diseases. Front. Cell Dev. Biol. 9, 686548.

   1400
   10.3389/fcell.2021.686548.
- 1401 1402 67. Ferrero, M.R., Tavares, L.P., and Garcia, C.C. (2022). The Dual Role of CCR5 in the Course of Influenza Infection: Exploring Treatment Opportunities. Front. Immunol. *12*, 826621. 10.3389/fimmu.2021.826621.
- 1403 68. Cox, A., Cevik, H., Feldman, H.A., Canaday, L.M., Lakes, N., and Waggoner, S.N. (2021). Targeting natural killer cells to enhance vaccine responses. Trends in Pharmacological Sciences *42*, 789–801. 10.1016/j.tips.2021.06.004.
- 1405<br/>140669. Frank, K., and Paust, S. (2020). Dynamic Natural Killer Cell and T Cell Responses to Influenza Infection. Front. Cell.<br/>Infect. Microbiol. 10, 425. 10.3389/fcimb.2020.00425.
- 1407
  1408
  1408
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409
  1409</l
- 1410
  1411
  1412
  71. Lee, N., Shin, M.S., Kang, K.S., Yoo, S.-A., Mohanty, S., Montgomery, R.R., Shaw, A.C., and Kang, I. (2014). Human monocytes have increased IFN-γ-mediated IL-15 production with age alongside altered IFN-γ receptor signaling. Clinical Immunology *152*, 101–110. 10.1016/j.clim.2014.03.003.
- 1413<br/>141472. Bouchard, A., Ratthé, C., and Girard, D. (2004). Interleukin-15 delays human neutrophil apoptosis by intracellular events<br/>and not via extracellular factors: role of McI-1 and decreased activity of caspase-3 and caspase-8. Journal of Leukocyte<br/>Biology 75, 893–900. 10.1189/jlb.1103585.
- 1416 1417 73. Moretta, A. (2002). Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2, 957–965. 10.1038/nri956.
- 1418
   74.
   Graca, L., Faria, A.C., and Ribeiro, R.M. (2023). Illuminating a blind spot in SARS-CoV-2 immunity. Nat Immunol 24, 889– 890. 10.1038/s41590-023-01518-w.
- 75. Zhang, W., Kedzierski, L., Chua, B.Y., Mayo, M., Lonzi, C., Rigas, V., Middleton, B.F., McQuilten, H.A., Rowntree, L.C., Allen, L.F., et al. (2023). Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities. Nat Immunol *24*, 966–978. 10.1038/s41590-023-01508-y.
- 1423 1424 76. Fuhrer, T., Heer, D., Begemann, B., and Zamboni, N. (2011). High-Throughput, Accurate Mass Metabolome Profiling of Cellular Extracts by Flow Injection–Time-of-Flight Mass Spectrometry. Anal. Chem. *83*, 7074–7080. 10.1021/ac201267k.
- 1425
  1426
  1426
  1427
  1428
  77. Arshad, H., Siokis, A., Franke, R., Habib, A., Alfonso, J.C.L., Poliakova, Y., Lücke, E., Michaelis, K., Brönstrup, M., Meyer-Hermann, M., et al. (2022). Reprogramming of Amino Acid Metabolism Differs between Community-Acquired Pneumonia and Infection-Associated Exacerbation of Chronic Obstructive Pulmonary Disease. Cells *11*, 2283.
  10.3390/cells11152283.
- 1429
  1430
  1431
  78. Assarsson, E., Lundberg, M., Holmquist, G., Björkesten, J., Bucht Thorsen, S., Ekman, D., Eriksson, A., Rennel Dickens, E., Ohlsson, S., Edfeldt, G., et al. (2014). Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability. PLoS ONE *9*, e95192. 10.1371/journal.pone.0095192.
- 1432<br/>143379.Patro, R., Duggal, G., Love, M.I., Irizarry, R.A., and Kingsford, C. (2017). Salmon provides fast and bias-aware<br/>quantification of transcript expression. Nat Methods 14, 417–419. 10.1038/nmeth.4197.
- 1434<br/>143580.Soneson, C., Love, M.I., and Robinson, M.D. (2016). Differential analyses for RNA-seq: transcript-level estimates improve<br/>gene-level inferences. F1000Res 4, 1521. 10.12688/f1000research.7563.2.
- 1436<br/>143781. Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., and Smyth, G.K. (2015). limma powers differential<br/>expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research 43, e47–e47.<br/>10.1093/nar/gkv007.
- 1439
   1440
   82. Law, C.W., Chen, Y., Shi, W., and Smyth, G.K. (2014). voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol *15*, R29. 10.1186/gb-2014-15-2-r29.

- 1441
  83. Wishart, D.S., Feunang, Y.D., Marcu, A., Guo, A.C., Liang, K., Vázquez-Fresno, R., Sajed, T., Johnson, D., Li, C., Karu, N., et al. (2018). HMDB 4.0: the human metabolome database for 2018. Nucleic Acids Research 46, D608–D617. 10.1093/nar/gkx1089.
- 1444
  1445
  1446
  84. Wishart, D.S., Feunang, Y.D., Guo, A.C., Lo, E.J., Marcu, A., Grant, J.R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018). DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Research *46*, D1074–D1082.
  10.1093/nar/gkx1037.
- 144785.Kamburov, A., Cavill, R., Ebbels, T.M.D., Herwig, R., and Keun, H.C. (2011). Integrated pathway-level analysis of<br/>transcriptomics and metabolomics data with IMPaLA. Bioinformatics 27, 2917–2918. 10.1093/bioinformatics/btr499.
- 1449<br/>145086. Smoot, M.E., Ono, K., Ruscheinski, J., Wang, P.-L., and Ideker, T. (2011). Cytoscape 2.8: new features for data<br/>integration and network visualization. Bioinformatics 27, 431–432. 10.1093/bioinformatics/btq675.

1451

1452





Time

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CAll rightsiensprup da No TRUSE20 were without provident of NRS: 674 genes



(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Proteins All rights reser**Ded**, Nor Dege (IDM)ed without permission vs Day 0 (NR)



F

A

С

D

Percentage



# Figure 3



Pyrrole-2-carboxylic acid

Metabolites

Figure 4



Figure 5

2

0

-2

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Áll rights reserved. No reuse allowed without permission. В



Long chain fatty acids